162 results on '"Marina Kvaskoff"'
Search Results
2. Quality of life among French breast cancer survivors in comparison with cancer-free women: the Seintinelles study
- Author
-
Alexandra-Cristina Paunescu, Marie Préau, Cyrille Delpierre, Guillemette Jacob, Myriam Pannard, Lidia Delrieu, and Marina Kvaskoff
- Subjects
Seintinelles ,Breast cancer survivors ,Cancer-free women ,Health-related quality of life ,Locus of control ,Coping ,Gynecology and obstetrics ,RG1-991 ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Health-Related Quality of life (HRQoL) in cancer survivors can be significantly affected in the long-term by various consequences resulting from differing levels of severity of cancer and its treatments. Our objective was to identify factors associated with HRQoL in breast cancer survivors (BCSs) and cancer-free women (CFWs). Methods We conducted a cross-sectional study in Seintinelles volunteers who answered online questionnaires between September 15, 2020 and February 5, 2021. HRQoL was measured using the World Health Organization Quality of Life–BREF questionnaire. We collected data on sociodemographic and health-related factors, lifestyle habits, coping mechanisms, locus of control, and health literacy. SAS version 9.4 statistical software was used for analyses. We performed descriptive analyses of the characteristics of the participants in each group and compared these characteristics between the two groups using the Chi2 test or the Student t-test. The adjusted means of the scores of different psychometric scales were calculated and compared using the method of least squares to fit general linear models (GLM) while adjusting for various factors. Multiple linear or multiple logistic regression models were used to assess the factors associated with WHOQOL-BREF scores, separately, in the two groups of participants. Results The study involved 722 BCSs and 1359 CFWs aged 26–75 years. BCSs had significantly lower physical health scores and were less likely to be satisfied with their health compared to CFWs (59.5 vs. 63.2, p 22) of internal locus of control); or inversely associated (neurological and sleep problems, over two medical consultations/year). In BCSs, treatment by mastectomy or radiation therapy/brachytherapy, a short-time since diagnosis, current cancer therapy, and presence of sequalae were inversely associated with physical health. BCSs’ health satisfaction was diminished with lower values of coping by positive thinking (≤ 14) and seeking social support (≤ 18). Conclusions HRQoL can be improved by developing strategies that increase internal locus of control and coping (positive thinking, problem-solving and seeking social support), and through health literacy.
- Published
- 2024
- Full Text
- View/download PDF
3. Stressful experiences impact clinical symptoms in people with endometriosis
- Author
-
Lysia Demetriou, Christian M Becker, Beatriz Martínez-Burgo, Adriana L Invitti, Marina Kvaskoff, Razneen Shah, Emma Evans, Claire E Lunde, Emma Cox, Kurtis Garbutt, Krina T Zondervan, Elaine Fox, and Katy Vincent
- Subjects
endometriosis ,covid-19 ,survey ,women ,pandemic ,Reproduction ,QH471-489 ,Gynecology and obstetrics ,RG1-991 - Abstract
Endometriosis is a chronic condition that affects ~10% of women globally. Its symptoms include chronic pelvic pain, heavy periods and tiredness/fatigue, which have been associated with poorer quality of life and mental health. We aim to explore the impact of the COVID-19 pandemic on pain and fatigue symptoms and their interactions with the impact on mental health in people with endometriosis. This global cross-sectional online survey study collected data from 4717 adults with self-reported surgical/radiological diagnosis of endometriosis between May and June 2020. The survey included questions on the current status and changes of endometriosis symptoms (pelvic pain, tiredness/fatigue, and bleeding patterns), mental health, pain catastrophising, and the impact of the COVID-19 pandemic on the respondents’ lives. Compared to 6 months earlier, Respondents reported a marked worsening of their endometriosis symptoms (endometriosis-associated pain (39.3%; 95% CI: 37.7, 40.5), tiredness/fatigue (49.9%; 95% CI: 48.4, 51.2) and bleeding patterns (39.6%; 95% CI: 38.2, 41)) and mental health (38.6%; 95% CI: 37.2, 39.9). Those with a pre-existing mental health diagnosis (38.8%) were more likely to report their symptoms worsening. Worsening of pain and tiredness/fatigue was significantly correlated with worsening of mental health (P < 0.001). The relationship between changes in mental health and (a) change in pain and (b) change in fatigue was found to be weakly mediated by pain catastrophising scores (pain: B = 0.071, lower limit of confidence interval (LLCI) = 0.060, upper limit of confidence interval (ULCI) = 0.082, tiredness/ fatigue: B = 0.050, LLCI = 0.040, ULCI = 0.060). This study demonstrates that stressful experiences impact the physical and mental health of people with endometriosis. The findings highlight the need to consider psychological approaches in the holistic management of people with endometriosis.
- Published
- 2022
- Full Text
- View/download PDF
4. Circulating inflammatory biomarkers, adipokines and breast cancer risk—a case-control study nested within the EPIC cohort
- Author
-
Manon Cairat, Sabina Rinaldi, Anne-Sophie Navionis, Isabelle Romieu, Carine Biessy, Vivian Viallon, Anja Olsen, Anne Tjønneland, Agnès Fournier, Gianluca Severi, Marina Kvaskoff, Renée T. Fortner, Rudolf Kaaks, Krasimira Aleksandrova, Matthias B. Schulze, Giovanna Masala, Rosario Tumino, Sabina Sieri, Chiara Grasso, Amalia Mattiello, Inger T. Gram, Karina Standahl Olsen, Antonio Agudo, Pilar Amiano Etxezarreta, Maria-Jose Sánchez, Carmen Santiuste, Aurelio Barricarte, Evelyn Monninkhof, Anouk E. Hiensch, David Muller, Melissa A. Merritt, Ruth C. Travis, Elisabete Weiderpass, Marc J. Gunter, and Laure Dossus
- Subjects
Breast cancer ,Inflammation ,Biomarkers ,Menopausal status ,Anthropometry ,Medicine - Abstract
Abstract Background Inflammation has been hypothesized to play a role in the development and progression of breast cancer and might differently impact breast cancer risk among pre and postmenopausal women. We performed a nested case-control study to examine whether pre-diagnostic circulating concentrations of adiponectin, leptin, c-reactive protein (CRP), tumour necrosis factor-α, interferon-γ and 6 interleukins were associated with breast cancer risk, overall and by menopausal status. Methods Pre-diagnostic levels of inflammatory biomarkers were measured in plasma from 1558 case-control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. We used conditional logistic regression to estimate the odds ratios (ORs) of breast cancer at blood collection, per one standard deviation increase in biomarker concentration. Results Cases were diagnosed at a mean age of 61.4 years on average 8.6 years after blood collection. No statistically significant association was observed between inflammatory markers and breast cancer risk overall. In premenopausal women, borderline significant inverse associations were observed for leptin, leptin-to-adiponectin ratio and CRP [OR= 0.89 (0.77–1.03), OR= 0.88 (0.76–1.01) and OR= 0.87 (0.75–1.01), respectively] while positive associations were observed among postmenopausal women [OR= 1.16 (1.05–1.29), OR= 1.11 (1.01–1.23), OR= 1.10 (0.99–1.22), respectively]. Adjustment for BMI strengthened the estimates in premenopausal women [leptin: OR = 0.83 (0.68–1.00), leptin-to-adiponectin ratio: OR = 0.80 (0.66–0.97), CRP: OR = 0.85 (0.72–1.00)] but attenuated the estimates in postmenopausal women [leptin: OR = 1.09 (0.96–1.24), leptin-to-adiponectin ratio: OR = 1.02 (0.89–1.16), CRP: OR = 1.04 (0.92–1.16)]. Conclusions Associations between CRP, leptin and leptin-to-adiponectin ratio with breast cancer risk may represent the dual effect of obesity by menopausal status although this deserves further investigation.
- Published
- 2022
- Full Text
- View/download PDF
5. Increasing incidence and spatial hotspots of hospitalized endometriosis in France from 2011 to 2017
- Author
-
Joëlle Le Moal, Sarah Goria, Julie Chesneau, Arnaud Fauconnier, Marina Kvaskoff, Perrine De Crouy-Chanel, Vanessa Kahn, Emile Daraï, and Michel Canis
- Subjects
Medicine ,Science - Abstract
Abstract Endometriosis is a female hormone-dependent disease, possibly related to endocrine disruptor exposure. We aimed to monitor this disease nationwide in France and analyze spatial trends at a fine scale to explore possible environmental contributing risk factors. We conducted a retrospective national descriptive study from 2011 to 2017 in females aged 10 years old and over, using comprehensive hospital discharge data. Cases were identified using ICD-10 N80 codes and were localized at their municipality of residence. We defined incident cases as the first hospital stay of patients, without a stay in at least the previous 5 years. We performed statistical analyses according to age and type of endometriosis, and we modeled the temporal, spatial and spatiotemporal trends. We identified 207,462 incident cases of all-type hospitalized endometriosis (83,112 for non-adenomyosis cases). The crude incidence rate for the study period was 9.85/10,000 person-years (3.95/10,000 for non-adenomyosis cases). From 2011 to 2017, the risk of all-type endometriosis increased by 8.5% (95% CI: 3.9; 13.4) (by 3.6% (95% CI: 0.6; 6.8) for non-adenomyosis cases). The risk was geographically heterogeneous, with 20 high-risk hotspots, showing similar results for non-adenomyosis cases. Shifting practice patterns, improved awareness and healthcare disparities interlinked with environmental risk factors could explain these trends.
- Published
- 2022
- Full Text
- View/download PDF
6. Gender gap in annual preventive care services in France
- Author
-
Bamba Gaye, Hélène Hergault, Camille Lassale, Magalie Ladouceur, Eugenie Valentin, Maxime Vignac, Nicolas Danchin, Mor Diaw, Marina Kvaskoff, Sarah Chamieh, Frederique Thomas, Erin D. Michos, and Xavier Jouven
- Subjects
Preventive medicine ,Cardiovascular screening ,Gender gap ,Women ,Mortality ,Medicine (General) ,R5-920 - Abstract
Summary: Background: In France, screening for cardiovascular risk factors is recommended during annual preventive visits. However, data are lacking on the temporal trend in women's uptake to preventive care services, and in cardiovascular and mortality outcomes. The aim of the study was to investigate the participation and mortality of women in annual preventive care services in a major preventive medicine center in France. Method: Ee conducted repeated cross-sectional studies including a total of 366,270 individuals who had a first examination at the Centre d'Investigations Préventives et Cliniques, France, between January 1992 and December 2011. Findings: Women's participation was low below 50 years of age, then increases from 50 to 70 years, and is lower for women older than 70 years. The gap in female participation was more pronounced among individuals with high education, low social deprivation, and no depressive symptoms. Compared with the general population, the screened population had significantly lower standardized mortality ratios (SMRs) among both men and women, for all age ranges. Screened women aged 18-49 years showed a lower mortality gain compared with men of the same age; SMRs did not differ significantly by sex for individuals over 50 years. Interpretation: In this community-based sample, compared with men, women's participation to annual preventive care services was lower, and screened women had a lower mortality gain. Despite the demonstrated benefit of annual check-ups on health, there is a gender gap in adherence to preventive programs and in efficiency of screening programs, especially in the young age range. This gap in cardiovascular disease prevention may result in poorer cardiovascular health in women. Urgent adaptations to overcome this gender gap in preventive screening in France are warranted. Funding: Bamba Gaye is supported by the Fondation Recherche Médicale grant.
- Published
- 2022
- Full Text
- View/download PDF
7. Dietary intakes of dioxins and polychlorobiphenyls (PCBs) and breast cancer risk in 9 European countries
- Author
-
Thibault Fiolet, Corinne Casagrande, Geneviève Nicolas, Zsuzsanna Horvath, Pauline Frenoy, Elisabete Weiderpass, Verena Katzke, Rudolf Kaaks, Miguel Rodriguez-Barranco, Salvatore Panico, Carlotta Sacerdote, Jonas Manjer, Emily Sonestedt, Sara Grioni, Antonio Agudo, Charlotta Rylander, Therese Haugdahl Nøst, Guri Skeie, Anne Tjønneland, Ole Raaschou-Nielsen, Eva Ardanaz, Pilar Amiano, María Dolores Chirlaque López, Matthias B. Schulze, Maria Wennberg, Sophia Harlid, Manon Cairat, Marina Kvaskoff, Inge Huybrechts, and Francesca Romana Mancini
- Subjects
Breast cancer ,Dioxins ,Polychlorobiphenyls ,PCBs ,Diet ,Persistent pollutants ,Environmental sciences ,GE1-350 - Abstract
Background: Dioxins and polychlorobiphenyls (PCBs) are persistent organic pollutants that have demonstrated endocrine disrupting properties. Several of these chemicals are carcinogenic and positive associations have been suggested with breast cancer risk. In general population, diet represents the main source of exposure. Methods: Associations between dietary intake of 17 dioxins and 35 PCBs and breast cancer were evaluated in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort from nine European countries using multivariable Cox regressions. The present study included 318,607 women (mean ± SD age: 50.7 ± 9.7) with 13,241 incident invasive breast cancers and a median follow-up of 14.9 years (IQR = 13.5–16.4). Dietary intake of dioxins and PCBs was assessed combining EPIC food consumption data with food contamination data provided by the European Food Safety Authority. Results: Exposure to dioxins, dioxins + Dioxin-Like-PCBs, Dioxin-Like-PCBs (DL-PCBs), and Non-Dioxin-Like-PCBs (NDL-PCBs) estimated from reported dietary intakes were not associated with breast cancer incidence, with the following hazard ratios (HRs) and 95% confidence intervals for an increment of 1 SD: HRdioxins = 1.00 (0.98 to 1.02), HRdioxins+DL-PCB = 1.01 (0.98 to 1.03), HRDL-PCB = 1.01 (0.98 to 1.03), and HRNDL-PCB = 1.01 (0.99 to 1.03). Results remained unchanged when analyzing intakes as quintile groups, as well as when analyses were run separately per country, or separating breast cancer cases based on estrogen receptor status or after further adjustments on main contributing food groups to PCBs and dioxins intake and nutritional factors. Conclusions: This large European prospective study does not support the hypothesis of an association between dietary intake of dioxins and PCBs and breast cancer risk.
- Published
- 2022
- Full Text
- View/download PDF
8. Plasma concentration of brominated flame retardants and postmenopausal breast cancer risk: a nested case-control study in the French E3N cohort
- Author
-
Francesca Romana Mancini, German Cano-Sancho, Oceane Mohamed, Iris Cervenka, Hanane Omichessan, Philippe Marchand, Marie-Christine Boutron-Ruault, Patrick Arveux, Gianluca Severi, Jean-Philippe Antignac, and Marina Kvaskoff
- Subjects
Breast cancer ,Brominated flame retardants (BFRs) ,Pentabromodiphenyl ethers (PBDEs) ,Polybrominated biphenyls (PBBs) ,E3N cohort ,Biomonitoring ,Industrial medicine. Industrial hygiene ,RC963-969 ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Brominated flame retardants (BFRs) are lipophilic substances with endocrine-disrupting properties. To date, only few investigations, mainly retrospective case-control studies, have explored the link between internal levels of BFRs and the risk of breast cancer, leading to conflicting results. We investigated the associations between plasma concentrations of two main groups of BFRs, PBDEs (pentabromodiphenyl ethers) and PBBs (polybrominated biphenyls), and the risk of breast cancer in a nested case-control study. Methods A total of 197 incident breast cancer cases and 197 controls with a blood sample collected in 1994–1999 were included. Plasma levels of PBDE congeners (BDE-28, BDE-47, BDE-99, BDE-100, BDE153, BDE-154) and of PBB-153 were measured by gas chromatography coupled to high-resolution mass spectrometry. Conditional logistic regression models, adjusted for potential confounders, were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Results Women were aged 56 years on average at blood draw. All cases, except for one, were diagnosed after menopause, with an average age at diagnosis of 68 years. Overall, we found no evidence of an association between plasma levels of PBDEs and PBB-153 and postmenopausal breast cancer risk (log-concentrations of BFRs yielding non-statistically significant ORs of 0.87 to 1.07). The analysis showed a non-linear inverse association for BDE-100 and BDE-153 and postmenopausal breast cancer risk; nevertheless, these findings were statistically significant only when the exposure was modeled as ng/L plasma (third vs. first quintile: OR = 0.42, 95%CI = 0.19–0.93 and OR = 0.42, 95%CI = 0.18–0.98, respectively) and not when modeled as ng/gr of lipids (OR = 0.58, 95%CI = 0.27–1.25 and OR = 0.53, 95%CI = 0.25–1.17). These results were unchanged in stratified analyses by tumor hormone receptor expression or body mass index. Conclusions Our results suggest no clear association between internal levels of PBDEs and PBB-153 and the risk of breast cancer in postmenopausal women. However, these findings need to be carefully interpreted, taking into account limitations due to the limited number of women included in the study, the lack of information concerning genetic susceptibility of cases, and the unavailability of exposure assessment during critical windows of susceptibility for breast cancer. More studies are warranted to further investigate the relationships between PBDE and PBB exposure and breast cancer risk.
- Published
- 2020
- Full Text
- View/download PDF
9. Lifestyle factors and risk of multimorbidity of cancer and cardiometabolic diseases: a multinational cohort study
- Author
-
Heinz Freisling, Vivian Viallon, Hannah Lennon, Vincenzo Bagnardi, Cristian Ricci, Adam S. Butterworth, Michael Sweeting, David Muller, Isabelle Romieu, Pauline Bazelle, Marina Kvaskoff, Patrick Arveux, Gianluca Severi, Christina Bamia, Tilman Kühn, Rudolf Kaaks, Manuela Bergmann, Heiner Boeing, Anne Tjønneland, Anja Olsen, Kim Overvad, Christina C. Dahm, Virginia Menéndez, Antonio Agudo, Maria-Jose Sánchez, Pilar Amiano, Carmen Santiuste, Aurelio Barricarte Gurrea, Tammy Y. N. Tong, Julie A. Schmidt, Ioanna Tzoulaki, Konstantinos K. Tsilidis, Heather Ward, Domenico Palli, Claudia Agnoli, Rosario Tumino, Fulvio Ricceri, Salvatore Panico, H. Susan J. Picavet, Marije Bakker, Evelyn Monninkhof, Peter Nilsson, Jonas Manjer, Olov Rolandsson, Elin Thysell, Elisabete Weiderpass, Mazda Jenab, Elio Riboli, Paolo Vineis, John Danesh, Nick J. Wareham, Marc J. Gunter, and Pietro Ferrari
- Subjects
Healthy lifestyle ,Obesity ,Cancer and cardiometabolic multimorbidity ,Cancer ,Cardiovascular disease ,Diabetes ,Medicine - Abstract
Abstract Background Although lifestyle factors have been studied in relation to individual non-communicable diseases (NCDs), their association with development of a subsequent NCD, defined as multimorbidity, has been scarcely investigated. The aim of this study was to investigate associations between five lifestyle factors and incident multimorbidity of cancer and cardiometabolic diseases. Methods In this prospective cohort study, 291,778 participants (64% women) from seven European countries, mostly aged 43 to 58 years and free of cancer, cardiovascular disease (CVD), and type 2 diabetes (T2D) at recruitment, were included. Incident multimorbidity of cancer and cardiometabolic diseases was defined as developing subsequently two diseases including first cancer at any site, CVD, and T2D in an individual. Multi-state modelling based on Cox regression was used to compute hazard ratios (HR) and 95% confidence intervals (95% CI) of developing cancer, CVD, or T2D, and subsequent transitions to multimorbidity, in relation to body mass index (BMI), smoking status, alcohol intake, physical activity, adherence to the Mediterranean diet, and their combination as a healthy lifestyle index (HLI) score. Cumulative incidence functions (CIFs) were estimated to compute 10-year absolute risks for transitions from healthy to cancer at any site, CVD (both fatal and non-fatal), or T2D, and to subsequent multimorbidity after each of the three NCDs. Results During a median follow-up of 11 years, 1910 men and 1334 women developed multimorbidity of cancer and cardiometabolic diseases. A higher HLI, reflecting healthy lifestyles, was strongly inversely associated with multimorbidity, with hazard ratios per 3-unit increment of 0.75 (95% CI, 0.71 to 0.81), 0.84 (0.79 to 0.90), and 0.82 (0.77 to 0.88) after cancer, CVD, and T2D, respectively. After T2D, the 10-year absolute risks of multimorbidity were 40% and 25% for men and women, respectively, with unhealthy lifestyle, and 30% and 18% for men and women with healthy lifestyles. Conclusion Pre-diagnostic healthy lifestyle behaviours were strongly inversely associated with the risk of cancer and cardiometabolic diseases, and with the prognosis of these diseases by reducing risk of multimorbidity.
- Published
- 2020
- Full Text
- View/download PDF
10. Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and risk of in situ breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort
- Author
-
Nena Karavasiloglou, Anika Hüsing, Giovanna Masala, Carla H. van Gils, Renée Turzanski Fortner, Jenny Chang-Claude, Inge Huybrechts, Elisabete Weiderpass, Marc Gunter, Patrick Arveux, Agnès Fournier, Marina Kvaskoff, Anne Tjønneland, Cecilie Kyrø, Christina C. Dahm, Helene Tilma Vistisen, Marije F. Bakker, Maria-Jose Sánchez, María Dolores Chirlaque López, Carmen Santiuste, Eva Ardanaz, Virginia Menéndez, Antonio Agudo, Antonia Trichopoulou, Anna Karakatsani, Carlo La Vecchia, Eleni Peppa, Domenico Palli, Claudia Agnoli, Salvatore Panico, Rosario Tumino, Carlotta Sacerdote, Salma Tunå Butt, Signe Borgquist, Guri Skeie, Matthias Schulze, Timothy Key, Kay-Tee Khaw, Kostantinos K. Tsilidis, Merete Ellingjord-Dale, Elio Riboli, Rudolf Kaaks, Laure Dossus, Sabine Rohrmann, and Tilman Kühn
- Subjects
In situ breast cancer ,Cohort ,Lifestyle ,Prevention ,Lifestyle Score ,Medicine - Abstract
Abstract Background Even though in situ breast cancer (BCIS) accounts for a large proportion of the breast cancers diagnosed, few studies have investigated potential risk factors for BCIS. Their results suggest that some established risk factors for invasive breast cancer have a similar impact on BCIS risk, but large population-based studies on lifestyle factors and BCIS risk are lacking. Thus, we investigated the association between lifestyle and BCIS risk within the European Prospective Investigation into Cancer and Nutrition cohort. Methods Lifestyle was operationalized by a score reflecting the adherence to the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations. The recommendations utilized in these analyses were the ones pertinent to healthy body weight, physical activity, consumption of plant-based foods, energy-dense foods, red and processed meat, and sugary drinks and alcohol, as well as the recommendation on breastfeeding. Cox proportional hazards regression was used to assess the association between lifestyle score and BCIS risk. The results were presented as hazard ratios (HR) and corresponding 95% confidence intervals (CI). Results After an overall median follow-up time of 14.9 years, 1277 BCIS cases were diagnosed. Greater adherence to the WCRF/AICR cancer prevention recommendations was not associated with BCIS risk (HR = 0.98, 95% CI 0.93–1.03; per one unit of increase; multivariable model). An inverse association between the lifestyle score and BCIS risk was observed in study centers, where participants were recruited mainly via mammographic screening and attended additional screening throughout follow-up (HR = 0.85, 95% CI 0.73–0.99), but not in the remaining ones (HR = 0.99, 95% CI 0.94–1.05). Conclusions While we did not observe an overall association between lifestyle and BCIS risk, our results indicate that lifestyle is associated with BCIS risk among women recruited via screening programs and with regular screening participation. This suggests that a true inverse association between lifestyle habits and BCIS risk in the overall cohort may have been masked by a lack of information on screening attendance. The potential inverse association between lifestyle and BCIS risk in our analyses is consistent with the inverse associations between lifestyle scores and breast cancer risk reported from previous studies.
- Published
- 2019
- Full Text
- View/download PDF
11. Development and validation of circulating CA125 prediction models in postmenopausal women
- Author
-
Naoko Sasamoto, Ana Babic, Bernard A. Rosner, Renée T. Fortner, Allison F. Vitonis, Hidemi Yamamoto, Raina N. Fichorova, Linda J. Titus, Anne Tjønneland, Louise Hansen, Marina Kvaskoff, Agnès Fournier, Francesca Romana Mancini, Heiner Boeing, Antonia Trichopoulou, Eleni Peppa, Anna Karakatsani, Domenico Palli, Sara Grioni, Amalia Mattiello, Rosario Tumino, Valentina Fiano, N. Charlotte Onland-Moret, Elisabete Weiderpass, Inger T. Gram, J. Ramón Quirós, Leila Lujan-Barroso, Maria-Jose Sánchez, Sandra Colorado-Yohar, Aurelio Barricarte, Pilar Amiano, Annika Idahl, Eva Lundin, Hanna Sartor, Kay-Tee Khaw, Timothy J. Key, David Muller, Elio Riboli, Marc Gunter, Laure Dossus, Britton Trabert, Nicolas Wentzensen, Rudolf Kaaks, Daniel W. Cramer, Shelley S. Tworoger, and Kathryn L. Terry
- Subjects
Ovarian cancer ,Early detection ,CA125 ,Prediction model ,Postmenopausal ,Gynecology and obstetrics ,RG1-991 - Abstract
Abstract Background Cancer Antigen 125 (CA125) is currently the best available ovarian cancer screening biomarker. However, CA125 has been limited by low sensitivity and specificity in part due to normal variation between individuals. Personal characteristics that influence CA125 could be used to improve its performance as screening biomarker. Methods We developed and validated linear and dichotomous (≥35 U/mL) circulating CA125 prediction models in postmenopausal women without ovarian cancer who participated in one of five large population-based studies: Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, n = 26,981), European Prospective Investigation into Cancer and Nutrition (EPIC, n = 861), the Nurses’ Health Studies (NHS/NHSII, n = 81), and the New England Case Control Study (NEC, n = 923). The prediction models were developed using stepwise regression in PLCO and validated in EPIC, NHS/NHSII and NEC. Result The linear CA125 prediction model, which included age, race, body mass index (BMI), smoking status and duration, parity, hysterectomy, age at menopause, and duration of hormone therapy (HT), explained 5% of the total variance of CA125. The correlation between measured and predicted CA125 was comparable in PLCO testing dataset (r = 0.18) and external validation datasets (r = 0.14). The dichotomous CA125 prediction model included age, race, BMI, smoking status and duration, hysterectomy, time since menopause, and duration of HT with AUC of 0.64 in PLCO and 0.80 in validation dataset. Conclusions The linear prediction model explained a small portion of the total variability of CA125, suggesting the need to identify novel predictors of CA125. The dichotomous prediction model showed moderate discriminatory performance which validated well in independent dataset. Our dichotomous model could be valuable in identifying healthy women who may have elevated CA125 levels, which may contribute to reducing false positive tests using CA125 as screening biomarker.
- Published
- 2019
- Full Text
- View/download PDF
12. Background exposure to polychlorinated biphenyls and all-cause, cancer-specific, and cardiovascular-specific mortality: A systematic review and meta-analysis
- Author
-
Thibault Fiolet, Yahya Mahamat-Saleh, Pauline Frenoy, Marina Kvaskoff, and Francesca Romana Mancini
- Subjects
Polychlorinated biphenyls ,Mortality ,PCBs ,Cardiovascular diseases ,Cancer ,Cohort studies ,Environmental sciences ,GE1-350 - Abstract
Background: Polychlorinated biphenyls (PCBs) are a large family of man-made organic, ubiquitous, and persistent contaminants with endocrine-disrupting properties. PCBs have been associated with numerous adverse health effects and were classified as carcinogenic to humans, but their long-term impact on mortality risk in the general population is unknown. Objective: To conduct a systematic review and meta-analysis in order to assess whether background exposure levels of PCBs increase all-cause and cancer- and cardiovascular-specific mortality risk in the general population. Methods: We searched the Pubmed, Web of Science, Cochrane Library, and Embase databases for eligible studies up to 1st of January, 2021. We included cohort and nested-case control studies comparing the lowest vs. the highest background exposure level of PCBs in the general population and reporting data for all-cause mortality and/or cancer-/cardiovascular-specific mortality. Studies reporting occupational and accidental exposures were excluded. Random-effects meta-analysis was used to estimate summary relative risks (SRRs) and 95% confidence intervals (CIs). Heterogeneity across studies was assessed by I2 statistics, and publication bias both graphically and using Egger’s and Begg’s tests. Quality of included studies was assessed using the National Toxicology Program/Office of Health Assessment and Translation (NTP/OHAT). Confidence in the body of evidence and related level of evidence were assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) based on the NTP/OHAT framework. The protocol was registered in PROSPERO (CRD42020178079). Results: The initial search led to 2,132 articles. Eight prospective cohort studies met our inclusion criteria, leading to 72,852 participants including 17,805 deaths. Overall exposure to PCBs was not statistically significantly associated with all-cause mortality (SRR = 1.13, 95% CI = 0.90–1.41, n = 7 studies, low certainty); however, dietary exposure to PCBs was associated with an increased risk of cardiovascular-specific mortality (SRR = 1.38, 95% CI = 1.14–1.66, n = 3 studies, moderate certainty), while no association was found with cancer-specific mortality (SRR = 1.07, 95% CI = 0.72–1.59, n = 5 studies, low certainty). Conclusion: Our meta-analysis suggests that background exposure to PCBs is associated with an increased risk of cardiovascular-specific mortality in the general population with a “moderate” level of evidence. These findings should be interpreted with caution given the small number of studies on mortality in the general population.
- Published
- 2021
- Full Text
- View/download PDF
13. The Global Impact of COVID-19 on the Care of People With Endometriosis
- Author
-
Lysia Demetriou, Emma Cox, Claire E. Lunde, Christian M. Becker, Adriana L. Invitti, Beatriz Martínez-Burgo, Marina Kvaskoff, Kurtis Garbutt, Emma Evans, Elaine Fox, Krina T. Zondervan, and Katy Vincent
- Subjects
endometriosis ,COVID-19 ,mental health support ,survey ,prioritisation ,Gynecology and obstetrics ,RG1-991 ,Women. Feminism ,HQ1101-2030.7 - Abstract
Endometriosis is a chronic condition affecting ~10% of women globally. Little is known about the impact of the coronavirus disease 2019 (COVID-19) pandemic on their care. This brief report is aimed to explore the impact of COVID-19 on the care of people with endometriosis around the world, their priorities in relation to their clinical care during and coming out of the pandemic, and whether they believed that endometriosis makes them more vulnerable to COVID-19. An internet-based survey collected data in five languages between May 11, 2020, and June 8, 2020. Only participants with a surgical or radiological diagnosis of endometriosis aged 18 years or over were included. A total of 6,729 eligible respondents completed the survey with 80.7% [95% CI (79.7, 81.6)] reporting a negative impact on their care. This included difficulties obtaining medication (20.3%), cancelled/postponed gynaecology appointments (50.0%), and cancelled/postponed procedures (37.2%). More than half worried that their endometrioses make them more vulnerable to COVID-19 [54.2%; 95% CI (53.0, 55.4)]. The top three priorities were remarkably consistent around the world: contact with gynaecologists, knowing when procedures would be performed, and support with mental health (20.3% prioritising this aspect during the pandemic and 13.0% as restrictions begin to ease). This study shows the substantial impact the COVID-19 pandemic has had on people with endometriosis and describes how they would like care prioritised moving forwards. The findings regarding significant support needs for mental health add further weight to the growing recognition of attending to such issues as part of good patient-centred care.
- Published
- 2021
- Full Text
- View/download PDF
14. Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts
- Author
-
Kuanrong Li, Garnet Anderson, Vivian Viallon, Patrick Arveux, Marina Kvaskoff, Agnès Fournier, Vittorio Krogh, Rosario Tumino, Maria-Jose Sánchez, Eva Ardanaz, María-Dolores Chirlaque, Antonio Agudo, David C. Muller, Todd Smith, Ioanna Tzoulaki, Timothy J. Key, Bas Bueno-de-Mesquita, Antonia Trichopoulou, Christina Bamia, Philippos Orfanos, Rudolf Kaaks, Anika Hüsing, Renée T. Fortner, Anne Zeleniuch-Jacquotte, Malin Sund, Christina C. Dahm, Kim Overvad, Dagfinn Aune, Elisabete Weiderpass, Isabelle Romieu, Elio Riboli, Marc J. Gunter, Laure Dossus, Ross Prentice, and Pietro Ferrari
- Subjects
Breast cancer ,Risk prediction ,Estrogen receptor ,Prospective cohort ,EPIC ,WHI ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Few published breast cancer (BC) risk prediction models consider the heterogeneity of predictor variables between estrogen-receptor positive (ER+) and negative (ER-) tumors. Using data from two large cohorts, we examined whether modeling this heterogeneity could improve prediction. Methods We built two models, for ER+ (ModelER+) and ER- tumors (ModelER-), respectively, in 281,330 women (51% postmenopausal at recruitment) from the European Prospective Investigation into Cancer and Nutrition cohort. Discrimination (C-statistic) and calibration (the agreement between predicted and observed tumor risks) were assessed both internally and externally in 82,319 postmenopausal women from the Women’s Health Initiative study. We performed decision curve analysis to compare ModelER+ and the Gail model (ModelGail) regarding their applicability in risk assessment for chemoprevention. Results Parity, number of full-term pregnancies, age at first full-term pregnancy and body height were only associated with ER+ tumors. Menopausal status, age at menarche and at menopause, hormone replacement therapy, postmenopausal body mass index, and alcohol intake were homogeneously associated with ER+ and ER- tumors. Internal validation yielded a C-statistic of 0.64 for ModelER+ and 0.59 for ModelER-. External validation reduced the C-statistic of ModelER+ (0.59) and ModelGail (0.57). In external evaluation of calibration, ModelER+ outperformed the ModelGail: the former led to a 9% overestimation of the risk of ER+ tumors, while the latter yielded a 22% underestimation of the overall BC risk. Compared with the treat-all strategy, ModelER+ produced equal or higher net benefits irrespective of the benefit-to-harm ratio of chemoprevention, while ModelGail did not produce higher net benefits unless the benefit-to-harm ratio was below 50. The clinical applicability, i.e. the area defined by the net benefit curve and the treat-all and treat-none strategies, was 12.7 × 10− 6 for ModelER+ and 3.0 × 10− 6 for ModelGail. Conclusions Modeling heterogeneous epidemiological risk factors might yield little improvement in BC risk prediction. Nevertheless, a model specifically predictive of ER+ tumor risk could be more applicable than an omnibus model in risk assessment for chemoprevention.
- Published
- 2018
- Full Text
- View/download PDF
15. Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort
- Author
-
Danja Sarink, Helena Schock, Theron Johnson, Jenny Chang-Claude, Kim Overvad, Anja Olsen, Anne Tjønneland, Patrick Arveux, Agnès Fournier, Marina Kvaskoff, Heiner Boeing, Anna Karakatsani, Antonia Trichopoulou, Carlo La Vecchia, Giovanna Masala, Claudia Agnoli, Salvatore Panico, Rosario Tumino, Carlotta Sacerdote, Carla H. van Gils, Petra H. M. Peeters, Elisabete Weiderpass, Antonio Agudo, Miguel Rodríguez-Barranco, José María Huerta, Eva Ardanaz, Leire Gil, Kay Tee Kaw, Julie A. Schmidt, Laure Dossus, Mathilde His, Dagfinn Aune, Elio Riboli, Rudolf Kaaks, and Renée T. Fortner
- Subjects
Breast cancer ,Reproductive, hormonal, and related factors ,Epidemiology ,Serum biomarkers of endogenous exposures ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Receptor activator of nuclear factor kappa-B (RANK)-signaling is involved in tumor growth and spread in experimental models. Binding of RANK ligand (RANKL) to RANK activates signaling, which is inhibited by osteoprotegerin (OPG). We have previously shown that circulating soluble RANKL (sRANKL) and OPG are associated with breast cancer risk. Here we extend these findings to provide the first data on pre-diagnosis concentrations of sRANKL and OPG and risk of breast cancer-specific and overall mortality after a breast cancer diagnosis. Methods Two thousand six pre- and postmenopausal women with incident invasive breast cancer (1620 (81%) with ER+ disease) participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort were followed-up for mortality. Pre-diagnosis concentrations of sRANKL and OPG were quantified in baseline serum samples using an enzyme-linked immunosorbent assay and electrochemiluminescent assay, respectively. Hazard ratios (HRs) and 95% confidence intervals (CIs) for breast cancer-specific and overall mortality were calculated using Cox proportional hazards regression models. Results Especially in women with ER+ disease, higher circulating OPG concentrations were associated with higher risk of breast cancer-specific (quintile 5 vs 1 HR 1.77 [CI 1.03, 3.04]; ptrend 0.10) and overall mortality (q5 vs 1 HR 1.39 [CI 0.94, 2.05]; ptrend 0.02). sRANKL and the sRANKL/OPG ratio were not associated with mortality following a breast cancer diagnosis. Conclusions High pre-diagnosis endogenous concentrations of OPG, the decoy receptor for RANKL, were associated with increased risk of death after a breast cancer diagnosis, especially in those with ER+ disease. These results need to be confirmed in well-characterized patient cohorts.
- Published
- 2018
- Full Text
- View/download PDF
16. Patterns of Ultraviolet Radiation Exposure and Skin Cancer Risk: the E3N-SunExp Study
- Author
-
Isabelle Savoye, Catherine M Olsen, David C Whiteman, Anne Bijon, Lucien Wald, Laureen Dartois, Françoise Clavel-Chapelon, Marie-Christine Boutron-Ruault, and Marina Kvaskoff
- Subjects
melanoma ,squamous cell carcinoma ,basal cell carcinoma ,sun exposure ,Medicine (General) ,R5-920 - Abstract
Background: While ultraviolet (UV) radiation exposure is a recognized risk factor for skin cancer, associations are complex and few studies have allowed a direct comparison of exposure profiles associated with cutaneous melanoma, basal-cell carcinoma (BCC), and squamous-cell carcinoma (SCC) within a single population. Methods: We examined associations between UV exposures and skin cancer risk in a nested case-control study within E3N, a prospective cohort of 98,995 French women born in 1925–1950. In 2008, a lifetime UV exposure questionnaire was sent to all reported skin cancer cases and three controls per case, which were matched on age, county of birth, and education. Analyses were performed using conditional logistic regression and included 366 melanoma cases, 1,027 BCC cases, 165 SCC cases, and 3,647 controls. Results: A history of severe sunburns
- Published
- 2018
- Full Text
- View/download PDF
17. Polyphenol Intake and Epithelial Ovarian Cancer Risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study
- Author
-
Catalina Londoño, Valerie Cayssials, Izar de Villasante, Marta Crous-Bou, Augustin Scalbert, Elisabete Weiderpass, Antonio Agudo, Anne Tjønneland, Anja Olsen, Kim Overvad, Verena Katzke, Matthias Schulze, Domenico Palli, Vittorio Krogh, Maria Santucci de Magistris, Rosario Tumino, Fulvio Ricceri, Inger T. Gram, Charlotta Rylander, Guri Skeie, Maria-Jose Sánchez, Pilar Amiano, José María Huerta, Aurelio Barricarte, Hanna Sartor, Emily Sonestedt, Anders Esberg, Annika Idahl, Yahya Mahamat-Saleh, Nasser Laouali, Marina Kvaskoff, Renée Turzanski-Fortner, and Raul Zamora-Ros
- Subjects
ovarian cancer ,polyphenols ,flavonoids ,intake ,cohort ,EPIC ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Despite some epidemiological evidence on the protective effects of polyphenol intake on epithelial ovarian cancer (EOC) risk from case-control studies, the evidence is scarce from prospective studies and non-existent for several polyphenol classes. Therefore, we aimed to investigate the associations between the intake of total, classes and subclasses of polyphenols and EOC risk in a large prospective study. The study was conducted in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, which included 309,129 adult women recruited mostly from the general population. Polyphenol intake was assessed through validated country-specific dietary questionnaires and the Phenol-Explorer database. During a mean follow-up of 14 years, 1469 first incident EOC cases (including 806 serous, 129 endometrioid, 102 mucinous, and 67 clear cell tumours) were identified. In multivariable-adjusted Cox regression models, the hazard ratio in the highest quartile of total polyphenol intake compared with the lowest quartile (HRQ4vsQ1) was 1.14 (95% CI 0.94–1.39; p-trend = 0.11). Similarly, the intake of most classes and subclasses of polyphenols were not related to either overall EOC risk or any EOC subtype. A borderline statistically significant positive association was observed between phenolic acid intake (HRQ4vsQ1 = 1.20, 95% CI 1.01–1.43; p-trend = 0.02) and EOC risk, especially for the serous subtype and in women with obesity, although these associations did not exceed the Bonferroni correction threshold. The current results do not support any association between polyphenol intake and EOC in our large European prospective study. Results regarding phenolic acid intake need further investigation
- Published
- 2021
- Full Text
- View/download PDF
18. Association between melanocytic nevi and risk of breast diseases: The French E3N prospective cohort.
- Author
-
Marina Kvaskoff, Anne Bijon, Sylvie Mesrine, Alice Vilier, Laura Baglietto, Agnès Fournier, Françoise Clavel-Chapelon, Laure Dossus, and Marie-Christine Boutron-Ruault
- Subjects
Medicine - Abstract
BACKGROUND: While melanocytic nevi have been associated with genetic factors and childhood sun exposure, several observations also suggest a potential hormonal influence on nevi. To test the hypothesis that nevi are associated with breast tumor risk, we explored the relationships between number of nevi and benign and malignant breast disease risk. METHODS AND FINDINGS: We prospectively analyzed data from E3N, a cohort of French women aged 40-65 y at inclusion in 1990. Number of nevi was collected at inclusion. Hazard ratios (HRs) for breast cancer and 95% confidence intervals (CIs) were calculated using Cox proportional hazards regression models. Associations of number of nevi with personal history of benign breast disease (BBD) and family history of breast cancer were estimated using logistic regression. Over the period 15 June 1990-15 June 2008, 5,956 incident breast cancer cases (including 5,245 invasive tumors) were ascertained among 89,902 women. In models adjusted for age, education, and known breast cancer risk factors, women with "very many" nevi had a significantly higher breast cancer risk (HR = 1.13, 95% CI = 1.01-1.27 versus "none"; ptrend = 0.04), although significance was lost after adjustment for personal history of BBD or family history of breast cancer. The 10-y absolute risk of invasive breast cancer increased from 3,749 per 100,000 women without nevi to 4,124 (95% CI = 3,674-4,649) per 100,000 women with "very many" nevi. The association was restricted to premenopausal women (HR = 1.40, ptrend = 0.01), even after full adjustment (HR = 1.34, ptrend = 0.03; phomogeneity = 0.04), but did not differ according to breast cancer type or hormone receptor status. In addition, we observed significantly positive dose-response relationships between number of nevi and history of biopsy-confirmed BBD (n = 5,169; ptrend
- Published
- 2014
- Full Text
- View/download PDF
19. Methylome analysis and epigenetic changes associated with menarcheal age.
- Author
-
Christiana A Demetriou, Jia Chen, Silvia Polidoro, Karin van Veldhoven, Cyrille Cuenin, Gianluca Campanella, Kevin Brennan, Françoise Clavel-Chapelon, Laure Dossus, Marina Kvaskoff, Dagmar Drogan, Heiner Boeing, Rudolf Kaaks, Angela Risch, Dimitrios Trichopoulos, Pagona Lagiou, Giovanna Masala, Sabina Sieri, Rosario Tumino, Salvatore Panico, J Ramón Quirós, María-José Sánchez Perez, Pilar Amiano, José María Huerta Castaño, Eva Ardanaz, Charlotte Onland-Moret, Petra Peeters, Kay-Tee Khaw, Nick Wareham, Timothy J Key, Ruth C Travis, Isabelle Romieu, Valentina Gallo, Marc Gunter, Zdenko Herceg, Kyriacos Kyriacou, Elio Riboli, James M Flanagan, and Paolo Vineis
- Subjects
Medicine ,Science - Abstract
Reproductive factors have been linked to both breast cancer and DNA methylation, suggesting methylation as an important mechanism by which reproductive factors impact on disease risk. However, few studies have investigated the link between reproductive factors and DNA methylation in humans. Genome-wide methylation in peripheral blood lymphocytes of 376 healthy women from the prospective EPIC study was investigated using LUminometric Methylation Assay (LUMA). Also, methylation of 458877 CpG sites was additionally investigated in an independent group of 332 participants of the EPIC-Italy sub-cohort, using the Infinium HumanMethylation 450 BeadChip. Multivariate logistic regression and linear models were used to investigate the association between reproductive risk factors and genome wide and CpG-specific DNA methylation, respectively. Menarcheal age was inversely associated with global DNA methylation as measured with LUMA. For each yearly increase in age at menarche, the risk of having genome wide methylation below median level was increased by 32% (OR:1.32, 95%CI:1.14-1.53). When age at menarche was treated as a categorical variable, there was an inverse dose-response relationship with LUMA methylation levels (OR(12-14 vs. ≤11 yrs):1.78, 95%CI:1.01-3.17 and OR(≥15 vs. ≤11 yrs):4.59, 95%CI:2.04-10.33; P for trend
- Published
- 2013
- Full Text
- View/download PDF
20. Health behaviour changes in female cancer survivors: The Seintinelles study
- Author
-
Alexandra-Cristina Paunescu, Marie Préau, Guillemette Jacob, Myriam Pannard, Lidia Delrieu, Cyrille Delpierre, and Marina Kvaskoff
- Subjects
Cancer Research ,Oncology ,Radiology, Nuclear Medicine and imaging ,Hematology ,General Medicine - Published
- 2023
21. Patients' Perspectives on How to Improve Endometriosis Care: A Large Qualitative Study Within the ComPaRe-Endometriosis e-Cohort
- Author
-
Solène Gouesbet, Marina Kvaskoff, Carolina Riveros, Élise Diard, Isabelle Pane, Zélia Goussé-Breton, Michelle Valenti, Marie Gabillet, Camille Garoche, Philippe Ravaud, and Viet-Thi Tran
- Subjects
General Medicine - Published
- 2023
22. Statin use and risk of cutaneous melanoma: a nationwide nested case–control study
- Author
-
Reza Ghiasvand, Leon A M Berge, Bettina K Andreassen, Adele C Green, Marie Al Rahmoun, Agnès Fournier, Marina Kvaskoff, Marit B Veierød, and Trude E Robsahm
- Subjects
Dermatology - Abstract
This nationwide nested case–control study examined the association between statin use and risk of cutaneous melanoma. We included 12 048 adult patients with melanoma and 117 895 randomly selected cancer-free controls, matched on age and sex. Cancer data were obtained from the Cancer Registry of Norway and data on drug use was retrieved from the Norwegian Prescription Database. We estimated rate ratios with 95% confidence intervals and conducted sensitivity analyses. We observed an inverse dose–response association between statin use and melanoma risk, stronger in women. The highest statin intake was associated with a reduced risk of melanoma, particularly on the head/neck and lower limbs. Our finding may have implications for melanoma prevention in high-risk groups.
- Published
- 2023
23. Baseline and lifetime alcohol consumption and risk of skin cancer in the European Prospective Investigation into Cancer and Nutrition cohort ( <scp>EPIC</scp> )
- Author
-
Yahya Mahamat‐Saleh, Marie Al‐Rahmoun, Gianluca Severi, Reza Ghiasvand, Marit B. Veierod, Saverio Caini, Domenico Palli, Edoardo Botteri, Carlotta Sacerdote, Fulvio Ricceri, Marko Lukic, Maria J. Sánchez, Valeria Pala, Rosario Tumino, Paolo Chiodini, Pilar Amiano, Sandra Colorado‐Yohar, María‐Dolores Chirlaque, Eva Ardanaz, Catalina Bonet, Verena Katzke, Rudolf Kaaks, Matthias B. Schulze, Kim Overvad, Christina C. Dahm, Christian S. Antoniussen, Anne Tjønneland, Cecilie Kyrø, Bas Bueno‐de‐Mesquita, Jonas Manjer, Malin Jansson, Anders Esberg, Nagisa Mori, Pietro Ferrari, Elisabete Weiderpass, Marie‐Christine Boutron‐Ruault, Marina Kvaskoff, Mahamat-Saleh, Yahya, Al-Rahmoun, Marie, Severi, Gianluca, Ghiasvand, Reza, Veierod, Marit B, Caini, Saverio, Palli, Domenico, Botteri, Edoardo, Sacerdote, Carlotta, Ricceri, Fulvio, Lukic, Marko, Sánchez, Maria J, Pala, Valeria, Tumino, Rosario, Chiodini, Paolo, Amiano, Pilar, Colorado-Yohar, Sandra, Chirlaque, María-Dolore, Ardanaz, Eva, Bonet, Catalina, Katzke, Verena, Kaaks, Rudolf, Schulze, Matthias B, Overvad, Kim, Dahm, Christina C, Antoniussen, Christian S, Tjønneland, Anne, Kyrø, Cecilie, Bueno-de-Mesquita, Ba, Manjer, Jona, Jansson, Malin, Esberg, Ander, Mori, Nagisa, Ferrari, Pietro, Weiderpass, Elisabete, Boutron-Ruault, Marie-Christine, and Kvaskoff, Marina
- Subjects
Male ,Cancer och onkologi ,Cancer Research ,Skin Neoplasms ,Alcohol Drinking ,alcohol ,keratinocyte cancers ,Public Health, Global Health, Social Medicine and Epidemiology ,Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi ,cutaneous melanoma ,cohort studies ,Oncology ,Carcinoma, Basal Cell ,Risk Factors ,Cancer and Oncology ,Carcinoma, Squamous Cell ,epidemiology ,Humans ,Female ,Prospective Studies ,Melanoma ,cohort studie - Abstract
Experimental evidence suggests that alcohol induces cutaneous carcinogenesis, yet epidemiological studies on the link between alcohol intake and skin cancer have been inconsistent. The European Prospective Investigation into Cancer and Nutrition (EPIC) is a prospective cohort initiated in 1992 in 10 European countries. Alcohol intake at baseline and average lifetime alcohol intake were assessed using validated country-specific dietary and lifestyle questionnaires. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated in Cox models. A total of 14 037 skin cancer cases (melanoma: n = 2457; basal-cell carcinoma (BCC): n = 8711; squamous-cell carcinoma (SCC): n = 1928; unknown: n = 941) were identified among 450 112 participants (average follow-up: 15 years). Baseline alcohol intake was positively associated with SCC (>15 vs 0.1-4.9 g/day: HR = 1.44, 95% CI = 1.17-1.77; Ptrend = .001), BCC (HR = 1.12, 95% CI = 1.01-1.23; Ptrend = .04), and melanoma risks in men (HR = 1.17, 95% CI = 0.95-1.44; Ptrend = .17), while associations were more modest in women (SCC: HR = 1.09, 95% CI = 0.90-1.30; Ptrend = .13; BCC: HR = 1.08, 95% CI = 1.00-1.17,Ptrend = .03; melanoma: HR = 0.93, 95% CI = 0.80-1.08, Ptrend = .13). Associations were similar for lifetime alcohol intake, with an attenuated linear trend. Lifetime liquor/spirit intake was positively associated with melanoma (fourth vs first quartile: HR = 1.47, 95% CI = 1.08-1.99; Ptrend = .0009) and BCC risks in men (HR = 1.17, 95% CI = 1.04-1.31;Ptrend = .14). Baseline and lifetime intakes of wine were associated with BCC risk (HR = 1.25 in men; HR = 1.11-1.12; in women). No statistically significant associations were found between beverage types and SCC risk. Intake of beer was not associated with skin cancer risk. Our study suggests positive relationships between alcohol intake and skin cancer risk, which may have important implications for the primary prevention of skin cancer. What's new? Drinking alcohol can make the skin more sensitive to sunlight and vulnerable to skin cancer. Here, the authors conducted a large prospective cohort study to evaluate whether alcohol consumption correlates with skin cancer risk. Among the 450 112 participants, there were 2457 cases of melanoma, 8711 of basal cell carcinoma, and 1928 of squamous cell carcinoma. There was a positive association between alcohol and all three cancer types, stronger in men than in women. The association varied somewhat by beverage type.
- Published
- 2022
24. Supplementary Tables 1-6 from Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort
- Author
-
Renée T. Fortner, Rudolf Kaaks, Elio Riboli, Melissa Merritt, Sabina Rinaldi, Mark Gunter, Laure Dossus, Ruth Travis, Kay Tee Khaw, Pilar Amiano, Eva Ardanaz, Maria-Dolores Chirlaque, Maria-José Sánchez, Antonio Agudo, Elisabete Weiderpass, Petra H. Peeters, Carla H. van Gils, H.B(as). Bueno-de-Mesquita, Carlotta Sacerdote, Rosario Tumino, Amalia Mattiello, Valeria Pala, Domenico Palli, Antonia Trichopoulou, Eleni-Maria Papatesta, Pagona Lagiou, Heiner Boeing, Marina Kvaskoff, Mathilde His, Marie-Christine Boutron-Ruault, Anne Tjønneland, Marianne Holm, Kim Overvad, Theron Johnson, Helena Schock, and Danja Sarink
- Abstract
Supplementary table 1. Correlations of sRANKL and the sRANKL/OPG ratio with select hormones among controls: EPIC cohort nested case-control study. Supplementary table 2. Distribution of covariates by quintiles of sRANKL. Supplementary table 3. Circulating concentrations of sRANKL and breast cancer risk by hormone-receptor subtype and menopausal status at blood collection. Supplementary table 4. The sRANKL/OPG ratio and breast cancer risk by hormone-receptor subtype and menopausal status at blood collection. Supplementary table 5. sRANKL additionally adjusted for continuous (log2) OPG and breast cancer risk by hormone-receptor subtype: EPIC nested case-control study. Supplementary table 6. sRANKL/OPG cross-classification based on median split of sRANKL and OPG and breast cancer risk by hormone-receptor subtype: EPIC nested case-control study.
- Published
- 2023
25. Data from High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium
- Author
-
Shelley S. Tworoger, Anne Zeleniuch-Jacquotte, Nicolas Wentzensen, Kala Visvanathan, Carla H. van Gils, Rosario Tumino, Antonia Trichopoulou, Anne Tjonneland, J. Ramón Quirós, Melissa A. Merritt, Anthony M. Magliocco, Marina Kvaskoff, Rudolf Kaaks, Annika Idahl, Patricia Hartge, Inger T. Gram, Renée T. Fortner, Laure Dossus, Alan A. Arslan, Naomi E. Allen, Britton Trabert, Elizabeth M. Poole, Mary K. Townsend, Adrianne R. Mallen, and Lauren C. Peres
- Abstract
Growing epidemiologic evidence supports chronic inflammation as a mechanism of ovarian carcinogenesis. An association between a circulating marker of inflammation, C-reactive protein (CRP), and ovarian cancer risk has been consistently observed, yet, potential heterogeneity of this association by tumor and patient characteristics has not been adequately explored. In this study, we pooled data from case–control studies nested within six cohorts in the Ovarian Cancer Cohort Consortium (OC3) to examine the association between CRP and epithelial ovarian cancer risk overall, by histologic subtype and by participant characteristics. CRP concentrations were measured from prediagnosis serum or plasma in 1,091 cases and 1,951 controls. Multivariable conditional logistic regression was used to estimate ORs and 95% confidence intervals (CI). When CRP was evaluated using tertiles, no associations with ovarian cancer risk were observed. A 67% increased ovarian cancer risk was found for women with CRP concentrations >10 mg/L compared with 10 mg/L was positively associated with risk of mucinous (OR = 9.67; 95% CI = 1.10–84.80) and endometrioid carcinoma (OR = 3.41; 95% CI = 1.07–10.92), and suggestively positive, although not statistically significant, for serous (OR = 1.43; 95% CI = 0.82–2.49) and clear cell carcinoma (OR = 2.05; 95% CI = 0.36–11.57; Pheterogeneity = 0.20). Heterogeneity was observed with oral contraceptive use (Pinteraction = 0.03), where the increased risk was present only among ever users (OR = 3.24; 95% CI = 1.62–6.47). This study adds to the existing evidence that CRP plays a role in ovarian carcinogenesis and suggests that inflammation may be particularly implicated in the etiology of endometrioid and mucinous carcinoma.Significance:C-reactive protein is involved in ovarian carcinogenesis, and chronic inflammation may be particularly implicated in the etiology of mucinous and endometrioid carcinomas.
- Published
- 2023
26. Data from KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case–Control Study
- Author
-
Rupal S. Bhatt, Venkata S. Sabbisetti, Joseph V. Bonventre, Prateek Khanna, Timothy J. Key, Maria-Dolores Chirlaque, Miguel Rodríguez-Barranco, J. Ramón Quirós, Antonio Agudo, Therese H. Nøst, Torkjel M. Sandanger, Elisabete Weiderpass, Salvatore Panico, Sabina Sieri, Domenico Palli, Anna Karakatsani, Carlo La Vecchia, Antonia Trichopoulou, Marina Kvaskoff, Vittorio Perduca, Gianluca Severi, H. Bas Bueno-de-Mesquita, Kim Overvad, Roel C.H. Vermeulen, Petra H.M. Peeters, Heiner Boeing, Paul Brennan, Konstantinos K. Tsilidis, Paolo Vineis, Amanda J. Cross, Mattias Johansson, Elio Riboli, David C. Muller, and Ghislaine Scelo
- Abstract
Purpose: Renal cell carcinoma (RCC) has the potential for cure with surgery when diagnosed at an early stage. Kidney injury molecule-1 (KIM-1) has been shown to be elevated in the plasma of RCC patients. We aimed to test whether plasma KIM-1 could represent a means of detecting RCC prior to clinical diagnosis.Experimental Design: KIM-1 concentrations were measured in prediagnostic plasma from 190 RCC cases and 190 controls nested within a population-based prospective cohort study. Cases had entered the cohort up to 5 years before diagnosis, and controls were matched on cases for date of birth, date at blood donation, sex, and country. We applied conditional logistic regression and flexible parametric survival models to evaluate the association between plasma KIM-1 concentrations and RCC risk and survival.Results: The incidence rate ratio (IRR) of RCC for a doubling in KIM-1 concentration was 1.71 [95% confidence interval (CI), 1.44–2.03, P = 4.1 × 10−23], corresponding to an IRR of 63.3 (95% CI, 16.2–246.9) comparing the 80th to the 20th percentiles of the KIM-1 distribution in this sample. Compared with a risk model including known risk factors of RCC (age, sex, country, body mass index, and tobacco smoking status), a risk model additionally including KIM-1 substantially improved discrimination between cases and controls (area under the receiver-operating characteristic curve of 0.8 compared with 0.7). High plasma KIM-1 concentrations were also associated with poorer survival (P = 0.0053).Conclusions: Plasma KIM-1 concentrations could predict RCC incidence up to 5 years prior to diagnosis and were associated with poorer survival. Clin Cancer Res; 24(22); 5594–601. ©2018 AACR.
- Published
- 2023
27. Supplementary Table 2 from The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3)
- Author
-
Nicolas Wentzensen, Anne Zeleniuch-Jacquotte, Alicja Wolk, Lynne R. Wilkens, Kala Visvanathan, Piet A. van den Brandt, Antonia Trichopoulou, Ruth C. Travis, Anthony J. Swerdlow, Veronica W. Setiawan, Leo J. Schouten, Catherine Schairer, Dale P. Sandler, Thomas E. Rohan, Kim Robien, Elio Riboli, Jenny N. Poynter, Ulrike Peters, Alpa V. Patel, Kim Overvad, N. Charlotte Onland-Moret, Roger L. Milne, I-Min Lee, James V. Lacey, Marina Kvaskoff, Synnove F. Knutsen, Victoria A. Kirsh, Rudolf Kaaks, Michael E. Jones, Annika Idahl, Judith Hoffman Bolton, Holly R. Harris, Inger T. Gram, Graham G. Giles, Mia M. Gaudet, Gary E. Fraser, Laure Dossus, Julie E. Buring, Louise A. Brinton, Leslie Bernstein, Alan A. Arslan, Pilar Amiano, Emily White, Patricia Hartge, Edwin S. Iversen, Renée T. Fortner, Mary K. Townsend, Katie M. O'Brien, Shelley S. Tworoger, and Britton Trabert
- Abstract
Associations between continuous total lifetime number of ovulatory cycles and ovarian cancer by tumor aggressiveness considering mutual adjustment for LOC component factors: duration of oral contraceptive use and pregnancies, Ovarian Cancer Cohort Consortium (OC3).
- Published
- 2023
28. Data from The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3)
- Author
-
Nicolas Wentzensen, Anne Zeleniuch-Jacquotte, Alicja Wolk, Lynne R. Wilkens, Kala Visvanathan, Piet A. van den Brandt, Antonia Trichopoulou, Ruth C. Travis, Anthony J. Swerdlow, Veronica W. Setiawan, Leo J. Schouten, Catherine Schairer, Dale P. Sandler, Thomas E. Rohan, Kim Robien, Elio Riboli, Jenny N. Poynter, Ulrike Peters, Alpa V. Patel, Kim Overvad, N. Charlotte Onland-Moret, Roger L. Milne, I-Min Lee, James V. Lacey, Marina Kvaskoff, Synnove F. Knutsen, Victoria A. Kirsh, Rudolf Kaaks, Michael E. Jones, Annika Idahl, Judith Hoffman Bolton, Holly R. Harris, Inger T. Gram, Graham G. Giles, Mia M. Gaudet, Gary E. Fraser, Laure Dossus, Julie E. Buring, Louise A. Brinton, Leslie Bernstein, Alan A. Arslan, Pilar Amiano, Emily White, Patricia Hartge, Edwin S. Iversen, Renée T. Fortner, Mary K. Townsend, Katie M. O'Brien, Shelley S. Tworoger, and Britton Trabert
- Abstract
Repeated exposure to the acute proinflammatory environment that follows ovulation at the ovarian surface and distal fallopian tube over a woman's reproductive years may increase ovarian cancer risk. To address this, analyses included individual-level data from 558,709 naturally menopausal women across 20 prospective cohorts, among whom 3,246 developed invasive epithelial ovarian cancer (2,045 serous, 319 endometrioid, 184 mucinous, 121 clear cell, 577 other/unknown). Cox models were used to estimate multivariable-adjusted HRs between lifetime ovulatory cycles (LOC) and its components and ovarian cancer risk overall and by histotype. Women in the 90th percentile of LOC (>514 cycles) were almost twice as likely to be diagnosed with ovarian cancer than women in the 10th percentile (Significance:Although ovarian cancer is rare, risk of most ovarian cancers doubles as the number of lifetime ovulatory cycles increases from approximately 300 to 500. Thus, identifying an important area for cancer prevention research.
- Published
- 2023
29. Supplementary Material (Table S1-S3, Figure S1-S2) from High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium
- Author
-
Shelley S. Tworoger, Anne Zeleniuch-Jacquotte, Nicolas Wentzensen, Kala Visvanathan, Carla H. van Gils, Rosario Tumino, Antonia Trichopoulou, Anne Tjonneland, J. Ramón Quirós, Melissa A. Merritt, Anthony M. Magliocco, Marina Kvaskoff, Rudolf Kaaks, Annika Idahl, Patricia Hartge, Inger T. Gram, Renée T. Fortner, Laure Dossus, Alan A. Arslan, Naomi E. Allen, Britton Trabert, Elizabeth M. Poole, Mary K. Townsend, Adrianne R. Mallen, and Lauren C. Peres
- Abstract
Table S1. Association between CRP and ovarian cancer risk by OC3 study Table S2. Association between CRP and ovarian cancer risk for various sensitivity analyses, including exclusion of PLCO, exclusion of women diagnosed within 2 years of blood draw, additional adjustment for aspirin use, and exclusion of women with cardiovascular disease Table S3. Association between CRP and ovarian cancer risk by time between blood draw and diagnosis Figure S1. Restricted cubic splines of the association between CRP and ovarian cancer risk using two approaches to identify CRP outliers Figure S2. Restricted cubic splines of the association between CRP and risk of serous and non-serous ovarian cancer
- Published
- 2023
30. Supplementary Table 1 from The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3)
- Author
-
Nicolas Wentzensen, Anne Zeleniuch-Jacquotte, Alicja Wolk, Lynne R. Wilkens, Kala Visvanathan, Piet A. van den Brandt, Antonia Trichopoulou, Ruth C. Travis, Anthony J. Swerdlow, Veronica W. Setiawan, Leo J. Schouten, Catherine Schairer, Dale P. Sandler, Thomas E. Rohan, Kim Robien, Elio Riboli, Jenny N. Poynter, Ulrike Peters, Alpa V. Patel, Kim Overvad, N. Charlotte Onland-Moret, Roger L. Milne, I-Min Lee, James V. Lacey, Marina Kvaskoff, Synnove F. Knutsen, Victoria A. Kirsh, Rudolf Kaaks, Michael E. Jones, Annika Idahl, Judith Hoffman Bolton, Holly R. Harris, Inger T. Gram, Graham G. Giles, Mia M. Gaudet, Gary E. Fraser, Laure Dossus, Julie E. Buring, Louise A. Brinton, Leslie Bernstein, Alan A. Arslan, Pilar Amiano, Emily White, Patricia Hartge, Edwin S. Iversen, Renée T. Fortner, Mary K. Townsend, Katie M. O'Brien, Shelley S. Tworoger, and Britton Trabert
- Abstract
Summary of 20 Ovarian Cancer Cohort Consortium (OC3) cohorts included in analysis of lifetime ovulatory cycles (LOC) and incident ovarian cancer.
- Published
- 2023
31. Supplementary Material from KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case–Control Study
- Author
-
Rupal S. Bhatt, Venkata S. Sabbisetti, Joseph V. Bonventre, Prateek Khanna, Timothy J. Key, Maria-Dolores Chirlaque, Miguel Rodríguez-Barranco, J. Ramón Quirós, Antonio Agudo, Therese H. Nøst, Torkjel M. Sandanger, Elisabete Weiderpass, Salvatore Panico, Sabina Sieri, Domenico Palli, Anna Karakatsani, Carlo La Vecchia, Antonia Trichopoulou, Marina Kvaskoff, Vittorio Perduca, Gianluca Severi, H. Bas Bueno-de-Mesquita, Kim Overvad, Roel C.H. Vermeulen, Petra H.M. Peeters, Heiner Boeing, Paul Brennan, Konstantinos K. Tsilidis, Paolo Vineis, Amanda J. Cross, Mattias Johansson, Elio Riboli, David C. Muller, and Ghislaine Scelo
- Abstract
Supplementary Table 1, Supplementary Figures 1 and 2
- Published
- 2023
32. Dietary antioxidant supplements and risk of keratinocyte cancers in women: a prospective cohort study
- Author
-
Yahya, Mahamat-Saleh, Isabelle, Savoye, Iris, Cervenka, Marie, Al-Rahmoun, Claire, Cadeau, Marie-Christine, Boutron-Ruault, and Marina, Kvaskoff
- Subjects
Keratinocytes ,Skin Neoplasms ,Nutrition and Dietetics ,Medicine (miscellaneous) ,Antioxidants ,Cohort Studies ,Carcinoma, Basal Cell ,Risk Factors ,Dietary Supplements ,Carcinoma, Squamous Cell ,Humans ,Female ,Prospective Studies ,Vitamin A - Abstract
Experimental studies suggested that antioxidants could protect against skin carcinomas. However, epidemiological studies on antioxidant supplement use in relation to basal-cell carcinoma (BCC) and squamous-cell carcinoma (SCC) risks yielded inconsistent findings, and few prospective studies have been conducted to date. We aimed to investigate the associations between antioxidant supplement intake and keratinocyte cancer (KC) risk.E3N is an ongoing prospective cohort initiated in 1990 and involving 98,995 French women aged 40-65 years at recruitment. Intakes of dietary antioxidants were estimated via a validated dietary questionnaire in 1993 and self-reported antioxidant supplement use was collected in 1995. We used Cox models to compute hazard ratios (HRs) and 95% confidence intervals (CIs) adjusted for age and skin cancer risk factors.Over 1995-2014, 2426 BCC and 451 SCC cases were diagnosed among 63,063 women. We found positive relationships between vitamin A supplement use and KC risk (HR = 1.37, 95% CI 1.15-1.62), particularly with BCC (HR = 1.40, 95% CI 1.17-1.69); and between vitamin E supplement use and risks of both BCC (HR = 1.21, 95% CI 1.03-1.52) and SCC (HR = 1.43, 95% CI 1.03-1.99). Intake of beta-carotene supplements was associated with an increased SCC risk (HR = 1.59, 95% CI 1.00-2.54). Vitamin C supplement use was not associated with KC risk. We found similar results when considering total antioxidant intake.Intakes of vitamin A or E supplements were associated with an increased KC risk in women. Further studies with information on doses and duration of supplement use and the ability to examine their underlying mechanisms are needed.
- Published
- 2022
33. ESHRE guideline: endometriosis
- Author
-
Christian M Becker, Attila Bokor, Oskari Heikinheimo, Andrew Horne, Femke Jansen, Ludwig Kiesel, Kathleen King, Marina Kvaskoff, Annemiek Nap, Katrine Petersen, Ertan Saridogan, Carla Tomassetti, Nehalennia van Hanegem, Nicolas Vulliemoz, Nathalie Vermeulen, Signe Altm??e, Baris Ata, Elizabeth Ball, Fabio Barra, Ercan Bastu, Alexandra Bianco-Anil, Ulla Breth Knudsen, R??ka Brubel, Julia Cambitzi, Astrid Cantineau, Ying Cheong, Angelos Daniilidis, Bianca De Bie, Caterina Exacoustos, Simone Ferrero, Tarek Gelbaya, Josepha Goetz-Collinet, Gernot Hudelist, Munawar Hussain, Tereza Indrielle-Kelly, Shaheen Khazali, Sujata Lalit Kumar, Umberto Leone Roberti Maggiore, Jacques W M Maas, Helen McLaughlin, Jos?? Metello, Velja Mijatovic, Yasaman Miremadi, Charles Muteshi, Michelle Nisolle, Engin Oral, George Pados, Dana Parades, Nicola Pluchino, Prasanna Raj Supramaniam, Maren Schick, Beata Seeber, Renato Seracchioli, Antonio Simone Lagan??, Andreas Stavroulis, Linda Tebache, G??rkan Uncu, Uschi Van den Broeck, Arno van Peperstraten, Attila Vereczkey, Albert Wolthuis, P??nar Yal????n Bahat, Chadi Yazbeck, Christian M Becker, Attila Bokor, Oskari Heikinheimo, Andrew Horne, Femke Jansen, Ludwig Kiesel, Kathleen King, Marina Kvaskoff, Annemiek Nap, Katrine Petersen, Ertan Saridogan, Carla Tomassetti, Nehalennia van Hanegem, Nicolas Vulliemoz, Nathalie Vermeulen, Signe Altm??e, Baris Ata, Elizabeth Ball, Fabio Barra, Ercan Bastu, Alexandra Bianco-Anil, Ulla Breth Knudsen, R??ka Brubel, Julia Cambitzi, Astrid Cantineau, Ying Cheong, Angelos Daniilidi, Bianca De Bie, Caterina Exacousto, Simone Ferrero, Tarek Gelbaya, Josepha Goetz-Collinet, Gernot Hudelist, Munawar Hussain, Tereza Indrielle-Kelly, Shaheen Khazali, Sujata Lalit Kumar, Umberto Leone Roberti Maggiore, Jacques W M Maa, Helen McLaughlin, Jos?? Metello, Velja Mijatovic, Yasaman Miremadi, Charles Muteshi, Michelle Nisolle, Engin Oral, George Pado, Dana Parade, Nicola Pluchino, Prasanna Raj Supramaniam, Maren Schick, Beata Seeber, Renato Seracchioli, Antonio Simone Lagan??, Andreas Stavrouli, Linda Tebache, G??rkan Uncu, Uschi Van den Broeck, Arno van Peperstraten, Attila Vereczkey, Albert Wolthui, P??nar Yal????n Bahat, Chadi Yazbeck, University of Helsinki, Clinicum, Department of Obstetrics and Gynecology, and HUS Gynecology and Obstetrics
- Subjects
endometriosis ,LAPAROSCOPIC EXCISION ,OVARIAN-CANCER ,surgery ,3123 Gynaecology and paediatrics ,ASSISTED REPRODUCTIVE TECHNOLOGY ,ADD-BACK THERAPY ,TERM-FOLLOW-UP ,CONSERVATIVE SURGERY ,fertility ,Reproductive Biology ,Science & Technology ,ESHRE guideline ,HORMONE AGONIST ,Other Research Radboud Institute for Health Sciences [Radboudumc 0] ,endometriosi ,Obstetrics & Gynecology ,pelvic pain ,General Medicine ,BIMANUAL PELVIC EXAMINATION ,adolescent ,CYCLIC ORAL-CONTRACEPTIVES ,INTRAUTERINE SYSTEM ,Life Sciences & Biomedicine ,guideline - Abstract
Main results and the role of chance: This guideline aims to help clinicians to apply best care for women with endometriosis. Although studies mostly focus on women of reproductive age, the guideline also addresses endometriosis in adolescents and postmenopausal women. The guideline outlines the diagnostic process for endometriosis, which challenges laparoscopy and histology as gold standard diagnostic tests. The options for treatment of endometriosis-associated pain symptoms include analgesics, medical treatments and surgery. Non-pharmacological treatments are also discussed. For management of endometriosis-associated infertility, surgical treatment and/or medically assisted reproduction are feasible. While most of the more recent studies confirm previous ESHRE recommendations, there are five topics in which significant changes to recommendations were required and changes in clinical practice are to be expected. Limitations reasons for caution: The guideline describes different management options but, based on existing evidence, no firm recommendations could be formulated on the most appropriate treatments. Also, for specific clinical issues, such as asymptomatic endometriosis or extrapelvic endometriosis, the evidence is too scarce to make evidence-based recommendations. Wider implications of the findings: The guideline provides clinicians with clear advice on best practice in endometriosis care, based on the best evidence currently available. In addition, a list of research recommendations is provided to stimulate further studies in endometriosis. Study question: How should endometriosis be diagnosed and managed based on the best available evidence from published literature? Summary answer: The current guideline provides 109 recommendations on diagnosis, treatments for pain and infertility, management of disease recurrence, asymptomatic or extrapelvic disease, endometriosis in adolescents and postmenopausal women, prevention and the association with cancer. What is known already: Endometriosis is a chronic condition with a plethora of presentations in terms of not only the occurrence of lesions, but also the presence of signs and symptoms. The most important symptoms include pain and infertility. Study design size duration: The guideline was developed according to the structured methodology for development of ESHRE guidelines. After formulation of key questions by a group of experts, literature searches and assessments were performed. Papers published up to 1 December 2020 and written in English were included in the literature review. Participants/materials setting methods: Based on the collected evidence, recommendations were formulated and discussed within specialist subgroups and then presented to the core guideline development group (GDG) until consensus was reached. A stakeholder review was organized after finalization of the draft. The final version was approved by the GDG and the ESHRE Executive Committee. Summary answer: The current guideline provides 109 recommendations on diagnosis, treatments for pain and infertility, management of disease recurrence, asymptomatic or extrapelvic disease, endometriosis in adolescents and postmenopausal women, prevention and the association with cancer. What is known already: Endometriosis is a chronic condition with a plethora of presentations in terms of not only the occurrence of lesions, but also the presence of signs and symptoms. The most important symptoms include pain and infertility. Study design size duration: The guideline was developed according to the structured methodology for development of ESHRE guidelines. After formulation of key questions by a group of experts, literature searches and assessments were performed. Papers published up to 1 December 2020 and written in English were included in the literature review. Participants/materials setting methods: Based on the collected evidence, recommendations were formulated and discussed within specialist subgroups and then presented to the core guideline development group (GDG) until consensus was reached. A stakeholder review was organized after finalization of the draft. The final version was approved by the GDG and the ESHRE Executive Committee. Main results and the role of chance: This guideline aims to help clinicians to apply best care for women with endometriosis. Although studies mostly focus on women of reproductive age, the guideline also addresses endometriosis in adolescents and postmenopausal women. The guideline outlines the diagnostic process for endometriosis, which challenges laparoscopy and histology as gold standard diagnostic tests. The options for treatment of endometriosis-associated pain symptoms include analgesics, medical treatments and surgery. Non-pharmacological treatments are also discussed. For management of endometriosis-associated infertility, surgical treatment and/or medically assisted reproduction are feasible. While most of the more recent studies confirm previous ESHRE recommendations, there are five topics in which significant changes to recommendations were required and changes in clinical practice are to be expected. Limitations reasons for caution: The guideline describes different management options but, based on existing evidence, no firm recommendations could be formulated on the most appropriate treatments. Also, for specific clinical issues, such as asymptomatic endometriosis or extrapelvic endometriosis, the evidence is too scarce to make evidence-based recommendations. Wider implications of the findings: The guideline provides clinicians with clear advice on best practice in endometriosis care, based on the best evidence currently available. In addition, a list of research recommendations is provided to stimulate further studies in endometriosis. Study funding/competing interests: The guideline was developed and funded by ESHRE, covering expenses associated with the guideline meetings, with the literature searches and with the dissemination of the guideline. The guideline group members did not receive payments. C.M.B. reports grants from Bayer Healthcare and the European Commission; Participation on a Data Safety Monitoring Board or Advisory Board with ObsEva (Data Safety Monitoring Group) and Myovant (Scientific Advisory Group). A.B. reports grants from FEMaLE executive board member and European Commission Horizon 2020 grant; consulting fees from Ethicon Endo Surgery, Medtronic; honoraria for lectures from Ethicon; and support for meeting attendance from Gedeon Richter; A.H. reports grants from MRC, NIHR, CSO, Roche Diagnostics, Astra Zeneca, Ferring; Consulting fees from Roche Diagnostics, Nordic Pharma, Chugai and Benevolent Al Bio Limited all paid to the institution; a pending patent on Serum endometriosis biomarker; he is also Chair of TSC for STOP-OHSS and CERM trials. O.H. reports consulting fees and speaker's fees from Gedeon Richter and Bayer AG; support for attending meetings from Gedeon-Richter, and leadership roles at the Finnish Society for Obstetrics and Gynecology and the Nordic federation of the societies of obstetrics and gynecology. L.K. reports consulting fees from Gedeon Richter, AstraZeneca, Novartis, Dr KADE/Besins, Palleos Healthcare, Roche, Mithra; honoraria for lectures from Gedeon Richter, AstraZeneca, Novartis, Dr KADE/Besins, Palleos Healthcare, Roche, Mithra; support for attending meetings from Gedeon Richter, AstraZeneca, Novartis, Dr KADE/Besins, Palleos Healthcare, Roche, Mithra; he also has a leadership role in the German Society of Gynecological Endocrinology (DGGEF). M.K. reports grants from French Foundation for Medical Research (FRM), Australian Ministry of Health, Medical Research Future Fund and French National Cancer Institute; support for meeting attendance from European Society for Gynaecological Endoscopy (ESGE), European Congress on Endometriosis (EEC) and ESHRE; She is an advisory Board Member, FEMaLe Project (Finding Endometriosis Using Machine Learning), Scientific Committee Chair for the French Foundation for Research on Endometriosis and Scientific Committee Chair for the ComPaRe-Endometriosis cohort. A.N. reports grants from Merck SA and Ferring; speaker fees from Merck SA and Ferring; support for meeting attendance from Merck SA; Participation on a Data Safety Monitoring Board or Advisory Board with Nordic Pharma and Merck SA; she also is a board member of medical advisory board, Endometriosis Society, the Netherlands (patients advocacy group) and an executive board member of the World Endometriosis Society. E.S. reports grants from National Institute for Health Research UK, Rosetrees Trust, Barts and the London Charity; Royalties from De Gruyter (book editor); consulting fees from Hologic; speakers fees from Hologic, Johnson & Johnson, Medtronic, Intuitive, Olympus and Karl Storz; Participation in the Medicines for Women's Health Expert Advisory Group with Medicines and Healthcare Products Regulatory Agency (MHRA); he is also Ambassador for the World Endometriosis Society. C.T. reports grants from Merck SA; Consulting fees from Gedeon Richter, Nordic Pharma and Merck SA; speaker fees from Merck SA, all paid to the institution; and support for meeting attendance from Ferring, Gedeon Richter and Merck SA. The other authors have no conflicts of interest to declare
- Published
- 2022
34. Dietary intakes of Dioxins and polychlorobiphenyls (PCBs) and mortality: EPIC cohort study in 9 European countries
- Author
-
Thibault Fiolet, Geneviève Nicolas, Corinne Casagrande, Zsuzsanna Horvath, Pauline Frenoy, Marina Kvaskoff, Inge Huybrechts, Francesca Romana Mancini, and EPIC on behalf of the EPIC Network
- Subjects
General Earth and Planetary Sciences ,General Environmental Science - Published
- 2022
35. Dietary intakes of dioxins and polychlorinated biphenyls (PCBs) and breast cancer risk in 9 European countries
- Author
-
Thibault Fiolet, Corinne Casagrande, Geneviève Nicolas, Zsuzsanna Horvath, Pauline Frenoy, Manon Cairat, Marina Kvaskoff, Inge Huybrechts, Francesca Romana-Mancini, and EPIC On Behalf of the EPIC Network
- Subjects
General Earth and Planetary Sciences ,General Environmental Science - Published
- 2022
36. Circulating vitamin D and breast cancer risk: an international pooling project of 17 cohorts
- Author
-
Kala Visvanathan, Alison M. Mondul, Anne Zeleniuch-Jacquotte, Molin Wang, Mitchell H. Gail, Shiaw-Shyuan Yaun, Stephanie J. Weinstein, Marjorie L. McCullough, A. Heather Eliassen, Nancy R. Cook, Claudia Agnoli, Martin Almquist, Amanda Black, Julie E. Buring, Chu Chen, Yu Chen, Tess Clendenen, Laure Dossus, Veronika Fedirko, Gretchen L. Gierach, Edward L. Giovannucci, Gary E. Goodman, Marc T. Goodman, Pascal Guénel, Göran Hallmans, Susan E. Hankinson, Ronald L. Horst, Tao Hou, Wen-Yi Huang, Michael E. Jones, Corrine E. Joshu, Rudolf Kaaks, Vittorio Krogh, Tilman Kühn, Marina Kvaskoff, I-Min Lee, Yahya Mahamat-Saleh, Johan Malm, Jonas Manjer, Gertraud Maskarinec, Amy E. Millen, Toqir K. Mukhtar, Marian L. Neuhouser, Trude E. Robsahm, Minouk J. Schoemaker, Sabina Sieri, Malin Sund, Anthony J. Swerdlow, Cynthia A. Thomson, Giske Ursin, Jean Wactawski-Wende, Ying Wang, Lynne R. Wilkens, Yujie Wu, Emilie Zoltick, Walter C. Willett, Stephanie A. Smith-Warner, and Regina G. Ziegler
- Subjects
Epidemiology ,Article - Abstract
Laboratory and animal research support a protective role for vitamin D in breast carcinogenesis, but epidemiologic studies have been inconclusive. To examine comprehensively the relationship of circulating 25-hydroxyvitamin D [25(OH)D] to subsequent breast cancer incidence, we harmonized and pooled participant-level data from 10 U.S. and 7 European prospective cohorts. Included were 10,484 invasive breast cancer cases and 12,953 matched controls. Median age (interdecile range) was 57 (42-68) years at blood collection and 63 (49-75) years at breast cancer diagnosis. Prediagnostic circulating 25(OH)D was either newly measured using a widely accepted immunoassay and laboratory or, if previously measured by the cohort, calibrated to this assay to permit using a common metric. Study-specific relative risks (RRs) for season-standardized 25(OH)D concentrations were estimated by conditional logistic regression and combined by random-effects models. Circulating 25(OH)D increased from a median of 22.6 nmol/L in consortium-wide decile 1 to 93.2 nmol/L in decile 10. Breast cancer risk in each decile was not statistically significantly different from risk in decile 5 in models adjusted for breast cancer risk factors, and no trend was apparent (P-trend = 0.64). Compared to women with sufficient 25(OH)D based on Institute of Medicine guidelines (50- 62.5 nmol/L), RRs were not statistically significantly different at either low concentrations ( 20 nmol/L, 3% of controls) or high concentrations (100- 125 nmol/L, 3% of controls; ≥ 125 nmol/L, 0.7% of controls). RR per 25 nmol/L increase in 25(OH)D was 0.99 [95% confidence intervaI (CI) 0.95-1.03]. Associations remained null across subgroups, including those defined by body mass index, physical activity, latitude, and season of blood collection. Although none of the associations by tumor characteristics reached statistical significance, suggestive inverse associations were seen for distant and triple negative tumors. Circulating 25(OH)D, comparably measured in 17 international cohorts and season-standardized, was not related to subsequent incidence of invasive breast cancer over a broad range in vitamin D status.
- Published
- 2022
37. Validity of self-reported endometriosis: a comparison across four cohorts
- Author
-
Julie R. Palmer, Marina Kvaskoff, Lauren A. Wise, Amy L. Shafrir, Kathryn L. Terry, Stacey A. Missmer, P. Vinayak, L. M. Katuska, and Z. O. Shuaib
- Subjects
medicine.medical_specialty ,media_common.quotation_subject ,Endometriosis ,Reproductive medicine ,Fertility ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Risk Factors ,medicine ,Humans ,Risk factor ,Stage (cooking) ,Child ,media_common ,030219 obstetrics & reproductive medicine ,business.industry ,Medical record ,Rehabilitation ,Obstetrics and Gynecology ,Original Articles ,medicine.disease ,Reproductive Medicine ,030220 oncology & carcinogenesis ,Family medicine ,Cohort ,Female ,Self Report ,business ,Cohort study - Abstract
STUDY QUESTION How accurately do women report a diagnosis of endometriosis on self-administered questionnaires? SUMMARY ANSWER Based on the analysis of four international cohorts, women self-report endometriosis fairly accurately with a > 70% confirmation for clinical and surgical records. WHAT IS KNOWN ALREADY The study of complex diseases requires large, diverse population-based samples, and endometriosis is no exception. Due to the difficulty of obtaining medical records for a condition that may have been diagnosed years earlier and for which there is no standardized documentation, reliance on self-report is necessary. Only a few studies have assessed the validity of self-reported endometriosis compared with medical records, with the observed confirmation ranging from 32% to 89%. STUDY DESIGN, SIZE, DURATION We compared questionnaire-reported endometriosis with medical record notation among participants from the Black Women’s Health Study (BWHS; 1995-2013), Etude Epidémiologique auprès de femmes de la Mutuelle Générale de l’Education Nationale (E3N; 1990-2006), Growing Up Today Study (GUTS; 2005–2016), and Nurses’ Health Study II (NHSII; 1989–1993 first wave, 1995–2007 second wave). PARTICIPANTS/MATERIALS, SETTING, METHODS Participants who had reported endometriosis on self-administered questionnaires gave permission to procure and review their clinical, surgical, and pathology medical records, yielding records for 827 women: 225 (BWHS), 168 (E3N), 85 (GUTS), 132 (NHSII first wave), and 217 (NHSII second wave). We abstracted diagnosis confirmation as well as American Fertility Society (AFS) or revised American Society of Reproductive Medicine (rASRM) stage and visualized macro-presentation (e.g. superficial peritoneal, deep endometriosis, endometrioma). For each cohort, we calculated clinical reference to endometriosis, and surgical- and pathologic-confirmation proportions. MAIN RESULTS AND THE ROLE OF CHANCE Confirmation was high—84% overall when combining clinical, surgical, and pathology records (ranging from 72% for BWHS to 95% for GUTS), suggesting that women accurately report if they are told by a physician that they have endometriosis. Among women with self-reported laparoscopic confirmation of their endometriosis diagnosis, confirmation of medical records was extremely high (97% overall, ranging from 95% for NHSII second wave to 100% for NHSII first wave). Importantly, only 42% of medical records included pathology reports, among which histologic confirmation ranged from 76% (GUTS) to 100% (NHSII first wave). Documentation of visualized endometriosis presentation was often absent, and details recorded were inconsistent. AFS or rASRM stage was documented in 44% of NHSII first wave, 13% of NHSII second wave, and 24% of GUTS surgical records. The presence/absence of deep endometriosis was rarely noted in the medical records. LIMITATIONS, REASONS FOR CAUTION Medical record abstraction was conducted separately by cohort-specific investigators, potentially introducing misclassification due to variation in abstraction protocols and interpretation. Additionally, information on the presence/absence of AFS/rASRM stage, deep endometriosis, and histologic findings were not available for all four cohort studies. WIDER IMPLICATIONS OF THE FINDINGS Variation in access to care and differences in disease phenotypes and risk factor distributions among patients with endometriosis necessitates the use of large, diverse population samples to subdivide patients for risk factor, treatment response and discovery of long-term outcomes. Women self-report endometriosis with reasonable accuracy (>70%) and with exceptional accuracy when women are restricted to those who report that their endometriosis had been confirmed by laparoscopic surgery (>94%). Thus, relying on self-reported endometriosis in order to use larger sample sizes of patients with endometriosis appears to be valid, particularly when self-report of laparoscopic confirmation is used as the case definition. However, the paucity of data on histologic findings, AFS/rASRM stage, and endometriosis phenotypic characteristics suggests that a universal requirement for harmonized clinical and surgical data documentation is needed if we hope to obtain the relevant details for subgrouping patients with endometriosis. STUDY FUNDING/COMPETING INTEREST(S) This project was supported by Eunice Kennedy Shriver National Institute of Child Health and Development grants HD48544, HD52473, HD57210, and HD94842, National Cancer Institute grants CA50385, R01CA058420, UM1CA164974, and U01CA176726, and National Heart, Lung, and Blood Institute grant U01HL154386. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. AS, SM, and KT were additionally supported by the J. Willard and Alice S. Marriott Foundation. MK was supported by a Marie Curie International Outgoing Fellowship within the 7th European Community Framework Programme (#PIOF-GA-2011-302078) and is grateful to the Philippe Foundation and the Bettencourt-Schueller Foundation for their financial support. Funders had no role in the study design, conduct of the study or data analysis, writing of the report, or decision to submit the article for publication. LA Wise has served as a fibroid consultant for AbbVie, Inc for the last three years and has received in-kind donations (e.g. home pregnancy tests) from Swiss Precision Diagnostics, Sandstone Diagnostics, Kindara.com, and FertilityFriend.com for the PRESTO cohort. SA Missmer serves as an advisory board member for AbbVie and a single working group service for Roche; neither are related to this study. No other authors have a conflict of interest to report. Funders had no role in the study design, conduct of the study or data analysis, writing of the report, or decision to submit the article for publication. TRIAL REGISTRATION NUMBER N/A.
- Published
- 2021
38. [Avenues of reflection for endometriosis research in France]
- Author
-
Jean, Rosenbaum, Nicolas, Bourdel, Saadi, Khochbin, Marina, Kvaskoff, Sachiko, Matsuzaki, Fatima, Mechta-Grigoriou, Nicola, Pluchino, Olivier, Sandra, and Daniel, Vaiman
- Subjects
Endometrium ,Uterus ,Endometriosis ,Quality of Life ,Humans ,Female ,Epigenesis, Genetic - Abstract
Endometriosis is a chronic disease in which lesions resembling endometrial tissue are found outside the uterus, mainly in the pelvis or abdomen. It may affect 10% of women of childbearing age. It is the cause of a significant alteration in quality of life and a major cost to the health system. Few research teams are working on this subject, and its pathophysiology is still poorly understood. This article proposes avenues of reflection for research on endometriosis in France, notably based on the mobilization of related scientific communities (involved in cancer, development, epigenetics, and neurosciences research studies).Des pistes de réflexion pour la recherche sur l’endométriose en France.L’endométriose est une maladie chronique dans laquelle des lésions ressemblant à du tissu endométrial se retrouvent hors de l’utérus, principalement dans la cavité abdomino-pelvienne. Cette maladie pourrait toucher 10 % des femmes en âge de procréer. Elle est à l’origine d’une importante altération de la qualité de vie et d’un coût majeur pour le système de santé. Peu d’équipes de recherche sont mobilisées sur ce sujet, et la physiopathologie de la maladie reste mal comprise. Nous proposons dans cet article des pistes de réflexion pour la recherche sur l’endométriose en France, fondées notamment sur la mobilisation de communautés scientifiques connexes (notamment celles impliquées dans la recherche sur le cancer, la biologie du développement, l’épigénétique, les neurosciences).
- Published
- 2022
39. Malignancy Risks Associated with Endometriosis: Epidemiology
- Author
-
Marina Kvaskoff and Stacey A. Missmer
- Published
- 2022
40. Premenopausal Use of Progestogens and Cutaneous Melanoma Risk: A French Prospective Cohort Study
- Author
-
Yahya Mahamat-Saleh, Marie Al Rahmoun, Agnès Fournier, Marina Kvaskoff, Marie-Christine Boutron-Ruault, and Iris Cervenka
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,Skin Neoplasms ,Epidemiology ,medicine.medical_treatment ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Melanoma ,Aged ,030304 developmental biology ,0303 health sciences ,Progestogen ,Proportional hazards model ,business.industry ,Hazard ratio ,Middle Aged ,medicine.disease ,Confidence interval ,Premenopause ,030220 oncology & carcinogenesis ,Cutaneous melanoma ,Female ,France ,Progestins ,business ,Cohort study - Abstract
We investigated the influence of premenopausal use of progestogens on melanoma using data from E3N (Etude Epidémiologique Auprès de Femmes de l’Education Nationale), a prospective cohort of 98,995 French women, aged 40–65 years at inclusion. We used Cox models to adjust for age and melanoma risk factors. Over 1992–2008, 540 melanoma cases were ascertained among 79,558 women. We found a modest association between self-reported progestogen use and melanoma risk (hazard ratio (HR) = 1.23, 95% confidence interval (CI) = 1.02, 1.47), which was reduced after adjustment for melanoma risk factors (HR = 1.15, 95% CI: 0.95, 1.39). There was no heterogeneity across types of progestogens (P = 0.22), and use of multiple progestogens was positively associated with melanoma risk (HR = 1.33, 95% CI: 1.04, 1.70). Among users, we found no relationship with duration of progestogen use, age at start and last use, and time since first and last use. Although our results did not show evidence of a confounding effect of sun exposure, progestogen users had lower levels of residential sun exposure and were more likely to report sunscreen use, suggesting specific sun exposure profiles in users. Our findings do not support a strong influence of progestogens on melanoma risk. Further research is needed to confirm these results.
- Published
- 2019
41. Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition
- Author
-
Salma Butt, Rudolf Kaaks, Agnès Fournier, Marina Kvaskoff, Elisabete Weiderpass, Karolin Isaksson, Matthias B. Schulze, Susana Merino, Reza Ghiasvand, Gianluca Severi, Eva Ardanaz, Ingrid Ljuslinder, Yahya Mahamat-Saleh, Bas Bueno-de-Mesquita, Renée T. Fortner, Sandra Colorado-Yohar, Marie Al Rahmoun, Salvatore Panico, Clio Dessinioti, Sabina Sieri, Carlotta Sacerdote, Antonia Trichopoulou, Katerina Niforou, Anne Tjønneland, Laure Dossus, Ruth C. Travis, Saverio Caini, Leire Gil Majuelo, Kay-Tee Khaw, Maria J. Sánchez, Marit B. Veierød, Anja Olsen, Sabina Rinaldi, Torkjel M. Sandanger, Iris Cervenka, Malin Jansson, Marie-Christine Boutron-Ruault, Rosario Tumino, Edoardo Botteri, Domenico Palli, and Leila Lujan-Barroso
- Subjects
Oncology ,Cancer Research ,Skin Neoplasms ,Time Factors ,Dones ,hormonal treatments ,030207 dermatology & venereal diseases ,0302 clinical medicine ,cohort studies ,Risk Factors ,Surveys and Questionnaires ,Epidemiology ,Skin cancer ,Medicine ,Prospective Studies ,Prospective cohort study ,Melanoma ,oral contraceptives ,Incidence ,Estrogen Replacement Therapy ,Confounding ,Hazard ratio ,Confounding Factors, Epidemiologic ,Middle Aged ,European Prospective Investigation into Cancer and Nutrition ,Europe ,Postmenopause ,030220 oncology & carcinogenesis ,epidemiology ,Female ,Cohort study ,Adult ,medicine.medical_specialty ,menopausal hormone therapy ,Contraceptives, Oral, Hormonal ,cutaneous melanoma ,03 medical and health sciences ,Breast cancer ,Internal medicine ,Humans ,VDP::Medisinske Fag: 700 ,Women ,Nutrició ,Càncer de pell ,Aged ,Proportional Hazards Models ,Nutrition ,business.industry ,medicine.disease ,VDP::Medical disciplines: 700 ,Premenopause ,Cutaneous melanoma ,business - Abstract
This is the peer reviewed version of the following article: Cervenka, I., Al Rahmoun, M., Mahamat-Saleh, Y., Fournier, A., Boutron-Ruault, M.-C., Severi, G. ... Kvaskoff, M. (2019). Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, which has been published in final form at https://doi.org/10.1002/ijc.32674. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Evidence suggests an influence of sex hormones on cutaneous melanoma risk, but epidemiologic findings are conflicting. We examined the associations between use of oral contraceptives (OCs) and menopausal hormone therapy (MHT) and melanoma risk in women participating in the European Prospective Investigation into Cancer and Nutrition (EPIC). EPIC is a prospective cohort study initiated in 1992 in 10 European countries. Information on exogenous hormone use at baseline was derived from country‐specific self‐administered questionnaires. We used Cox proportional hazards regression models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Over 1992–2015, 1,696 melanoma cases were identified among 334,483 women, whereof 770 cases among 134,758 postmenopausal women. There was a positive, borderline‐significant association between OC use and melanoma risk (HR = 1.12, 95% CI = 1.00–1.26), with no detected heterogeneity across countries (phomogeneity = 0.42). This risk increased linearly with duration of use (ptrend = 0.01). Among postmenopausal women, ever use of MHT was associated with a nonsignificant increase in melanoma risk overall (HR = 1.14, 95% CI = 0.97–1.43), which was heterogeneous across countries (phomogeneity = 0.05). Our findings do not support a strong and direct association between exogenous hormone use and melanoma risk. In order to better understand these relations, further research should be performed using prospectively collected data including detailed information on types of hormone, and on sun exposure, which may act as an important confounder or effect modifier on these relations.
- Published
- 2019
42. Mediterranean dietary pattern and skin cancer risk: A prospective cohort study in French women
- Author
-
Yahya Mahamat-Saleh, Antonia Trichopoulou, Francesca Romana Mancini, Iris Cervenka, Marie Al Rahmoun, Isabelle Savoye, Marie-Christine Boutron-Ruault, and Marina Kvaskoff
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,Skin Neoplasms ,Mediterranean diet ,Medicine (miscellaneous) ,Diet, Mediterranean ,Lower risk ,Cohort Studies ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Epidemiology ,medicine ,Humans ,Basal cell carcinoma ,Prospective Studies ,Prospective cohort study ,Aged ,Nutrition and Dietetics ,business.industry ,Cancer ,Middle Aged ,medicine.disease ,030220 oncology & carcinogenesis ,Female ,France ,Skin cancer ,business ,Cohort study - Abstract
Background The Mediterranean diet (MD) has been reported to be associated with lower cancer risk. However, while previous studies explored major single components of the MD, only 1 previous study has investigated adherence to the MD in relation to melanoma risk. Objective The aim of this study was to explore the relations between adherence to the MD and the risk of skin cancer, including melanomas, basal cell carcinomas (BCCs), and squamous cell carcinomas (SCCs). Design Etude Epidemiologique aupres de femmes de la Mutuelle Generale de l'Education Nationale (E3N) is a prospective cohort of 98,995 French women aged 40-65 y in 1990. Dietary data were collected via a validated food questionnaire in 1993. Adherence to the MD was assessed using a 9-unit dietary score that incorporates intakes of fruit, vegetables, legumes, cereal products, olive oil, fish, dairy products, meat products, and alcohol. We used Cox proportional hazards regression models to compute HRs and 95% CIs adjusted for age and main known skin cancer risk factors. Results From 1993 to 2008, a total of 2003 skin cancer cases were ascertained among 67,332 women, including 404 melanomas, 1367 BCCs, and 232 SCCs. Score of adherence to the MD was associated with lower risk of skin cancer (HR: 0.83; 95% CI: 0.73, 0.93 for high compared with low score, Ptrend = 0.001). MD score was also inversely and linearly associated with risks of melanoma (HR: 0.72; 95% CI: 0.54, 0.96; Ptrend = 0.02) and BCC (HR: 0.77; 95% CI: 0.66, 0.90; Ptrend = 0.0006) but not SCC (HR: 1.08; 95% CI: 0.75, 1.55; Ptrend = 0.68), although with no heterogeneity across skin cancer types (Pheterogeneity = 0.23). Conclusion These findings suggest that adherence to the MD is associated with a lower skin cancer risk in women, particularly melanoma and BCC. If confirmed in future research, these findings may have important implications in skin cancer prevention.
- Published
- 2019
43. Endogenous Circulating Sex Hormone Concentrations and Colon Cancer Risk in Postmenopausal Women: a Prospective Study and Meta-Analysis
- Author
-
Matthias B. Schulze, Ruth C. Travis, Rosario Tumino, Rudolf Kaaks, Agnès Fournier, Niki Dimou, Pekka Keski-Rahkonen, Amanda J. Cross, Salvatore Panico, Marina Kvaskoff, Renée T. Fortner, María José Sánchez, Gianluca Severi, Dagfinn Aune, Carlotta Sacerdote, Marc J. Gunter, Konstantinos K. Tsilidis, Bas Bueno-de-Mesquita, Inger T. Gram, Eva Ardanaz, Sandra Colorado-Yohar, Marit Waaseth, Audrey Gicquiau, Vittorio Krogh, Paula Jakszyn, Sabina Rinaldi, Nagisa Mori, Justin Harbs, Neil Murphy, Sophia Harlid, Giovanna Masala, Eleanor L. Watts, and Bethany Van Guelpen
- Subjects
Cancer Research ,Colorectal cancer ,Physiology ,chemistry.chemical_compound ,Sex hormone-binding globulin ,Sex Hormone-Binding Globulin ,Odds Ratio ,Testosterone ,Prospective Studies ,Prospective cohort study ,Gonadal Steroid Hormones ,Progesterone ,biology ,Estradiol ,VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801 ,Dehydroepiandrosterone Sulfate ,Middle Aged ,Europe ,Postmenopause ,Oncology ,Colonic Neoplasms ,Female ,Menopause ,AcademicSubjects/MED00010 ,Menopausa ,Estrone ,Dehydroepiandrosterone ,Article ,Càncer colorectal ,medicine ,Confidence Intervals ,Humans ,Androstenedione ,Cancer och onkologi ,business.industry ,Rectal Neoplasms ,Estrogens ,Odds ratio ,medicine.disease ,Logistic Models ,chemistry ,Cancer and Oncology ,Case-Control Studies ,biology.protein ,VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801 ,business - Abstract
This work was supported by the French National Cancer Institute (INCa SHSESP17, grant No. 2017-127 to N. Murphy). The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition PotsdamRehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (the Netherlands); Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology-ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Ska degrees ne and V_asterbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford) (United Kingdom)., Background: Observational studies have consistently reported that postmenopausal hormone therapy use is associated with lower colon cancer risk, but epidemiologic studies examining the associations between circulating concentrations of endogenous estrogens and colorectal cancer have reported inconsistent results. Methods: We investigated the associations between circulating concentrations of estrone, estradiol, free estradiol, testosterone, free testosterone, androstenedione, dehydroepiandrosterone (DHEA), progesterone, and sex hormone–binding globulin (SHBG) with colon cancer risk in a nested case-control study of 1028 postmenopausal European women (512 colon cancer cases, 516 matched controls) who were noncurrent users of exogenous hormones at blood collection. Multivariable conditional logistic regression models were used to compute odds ratios and 95% confidence intervals to evaluate the association between circulating sex hormones and colon cancer risk. We also conducted a dose-response meta-analysis of prospective studies of circulating estrone and estradiol with colorectal, colon, and rectal cancer risk in postmenopausal women. All statistical tests were 2-sided. Results: In the multivariable model, a nonstatistically significantly positive relationship was found between circulating estrone and colon cancer risk (odds ratio per log2 1-unit increment¼1.17 [95% confidence interval¼1.00 to 1.38]; odds ratioquartile4-quartile1¼1.33 [95% confidence interval¼0.89 to 1.97], Ptrend¼.20). Circulating concentrations of estradiol, free estradiol, testosterone, free testosterone, androstenedione, DHEA, progesterone, and SHBG were not associated with colon cancer risk. In the doseresponse meta-analysis, no clear evidence of associations were found between circulating estradiol and estrone concentrations with colorectal, colon, and rectal cancer risk. Conclusion: Our observational and meta-analysis results do not support an association between circulating concentrations of endogenous sex hormones and colon or rectal cancer in postmenopausal women., French National Cancer Institute (INCa SHSESP17) 2017-127, World Health Organization, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Danish Cancer Society, Ligue Contre le Cancer (France), Institut Gustave Roussy (France), Mutuelle Generale de l'Education Nationale (France), Institut National de la Sante et de la Recherche Medicale (Inserm), Deutsche Krebshilfe German Cancer Research Center (DKFZ) (Germany) German Institute of Human Nutrition Potsdam Rehbruecke (DIfE) (Germany), Federal Ministry of Education & Research (BMBF), Fondazione AIRC per la ricerca sul cancro, Compagnia di San Paolo Consiglio Nazionale delle Ricerche (CNR), Netherlands Government, World Cancer Research Fund International (WCRF), Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII) (Spain) Junta de Andalucia Regional Government of Asturias (Spain) Regional Government of Basque Country (Spain) Regional Government of Murcia (Spain) Regional Government of Navarra (Spain) Catalan Institute of Oncology-ICO (Spain), Swedish Cancer Society Swedish Research Council County Council of Skane (Sweden) County Council of Vasterbotten (Sweden), Cancer Research UK 14136 C8221/A29017 UK Research & Innovation (UKRI) Medical Research Council UK (MRC) 1000143 MR/M012190/1
- Published
- 2021
44. Associations between plasma levels of brominated flame retardants and methylation of DNA from peripheral blood: A cross-sectional study in a cohort of French women
- Author
-
Hanane Omichessan, Vittorio Perduca, Silvia Polidoro, Marina Kvaskoff, Thérèse Truong, German Cano-Sancho, Jean-Philippe Antignac, Laura Baglietto, Francesca Romana Mancini, and Gianluca Severi
- Subjects
Cross-Sectional Studies ,Halogenated Diphenyl Ethers ,Humans ,Female ,DNA ,DNA Methylation ,Biochemistry ,Methylation ,Gas Chromatography-Mass Spectrometry ,General Environmental Science ,Flame Retardants - Abstract
Brominated flame retardants (BFRs) are organic compounds that are widespread in the environment. Because of their persistence, they are able to bioaccumulate with major impacts on human health. It has been hypothesized that the effect of BFRs on human health is mediated by alterations of DNA methylation.The aim of this study was to examine the association between methylation of DNA extracted from peripheral blood and circulating levels of BFRs measured in plasma.We conducted a methylation wide association study on 336 blood samples from a study within the E3N (Etude Epidémiologique auprès de femmes de l'Education Nationale) cohort, a long-term longitudinal cohort of French women. DNA methylation at more than 850 000 cytosine-guanine dinucleotide (CpG) sites was measured with the Illumina Infinium HumanMethylation - EPIC BeadChip. Circulating levels of seven BFRs (BDE-28, BDE-47, BDE-99, BDE-100, BDE-153, BDE-154 and PBB-153) were measured by gas chromatography coupled to high-resolution mass spectrometry in plasma samples. The association between DNA methylation and BFRs plasma levels was assessed through linear mixed-effects models followed by gene-set enrichment analyses (GSEA).We identified 253 CpG sites whose methylation levels were significantly associated with exposure to BFRs after Bonferroni correction. For 50 of these CpGs the p-values were less than 2.2x10Exposure to BFRs appears to be related to numerous alterations in DNA methylation. These findings, if replicated in independent studies, provide insights into the biological and health effects of BFRs.
- Published
- 2021
45. Endometriosis and cancer: a systematic review and meta-analysis
- Author
-
Kathryn L. Terry, Nina Shigesi, Krina T. Zondervan, Holly R. Harris, Sawsan As-Sanie, Leslie V. Farland, Horace Roman, Yahya Mahamat-Saleh, Andrew W Horne, Christian M. Becker, Marina Kvaskoff, and Stacey A. Missmer
- Subjects
endometriosis ,medicine.medical_specialty ,bias ,Skin Neoplasms ,Endometriosis ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,cohort studies ,Internal medicine ,Cancer screening ,medicine ,cancer ,Humans ,Prospective Studies ,Prospective cohort study ,Melanoma ,030219 obstetrics & reproductive medicine ,endometrioma ,business.industry ,case-control studies ,Case-control study ,Obstetrics and Gynecology ,methodology ,Publication bias ,medicine.disease ,Cross-Sectional Studies ,Reproductive Medicine ,030220 oncology & carcinogenesis ,Meta-analysis ,Relative risk ,epidemiology ,Female ,business ,Cohort study - Abstract
BACKGROUND Endometriosis is an often chronic, inflammatory gynaecologic condition affecting 190 million women worldwide. Studies have reported an elevated cancer risk among patients with endometriosis. However, prior research has included methodologic issues that impede valid and robust interpretation. OBJECTIVE AND RATIONALE We conducted a meta-analysis of studies investigating the association between endometriosis and cancer risk and analysed the results by methodologic characteristics. We discuss the implications of cancer screening in patients and management challenges faced by clinicians. SEARCH METHODS We searched PubMed and Embase databases for eligible studies from inception through 24 October 2019. We included cohort and case-control studies examining the association between endometriosis and cancer risk; cross-sectional studies and case reports were excluded. Publications had to present risk/rate/odds estimates with 95% CI. Random effects meta-analysis was used to estimate summary relative risks (SRR) and CIs. Heterogeneity across studies was assessed by the Q test and I2 statistics, and publication bias using Egger's and Begg's tests. Risk of bias and quality of the included studies were assessed using the risk of bias in non-randomized studies of interventions (ROBINS-I) tool. OUTCOMES Forty-nine population-based case-control and cohort studies were included. Twenty-six studies were scored as having a ‘serious’/‘critical’ risk of bias, and the remaining 23 ‘low’/‘moderate’. Cancer-specific analyses showed a positive association between endometriosis and ovarian cancer risk (SRR = 1.93, 95% CI = 1.68–2.22; n = 24 studies) that was strongest for clear cell (SRR = 3.44, 95% CI = 2.82–4.42; n = 5 studies) and endometrioid (SRR = 2.33, 95% CI = 1.82–2.98; n = 5 studies) histotypes (Pheterogeneity < 0.0001), although with significant evidence of both heterogeneity across studies and publication bias (Egger’s and Begg’s P-values WIDER IMPLICATIONS Endometriosis was associated with a higher risk of ovarian and thyroid, and minimally (only 4% greater risk) with breast cancer, and with a lower risk of cervical cancer. However, this meta-analysis confirms that: a majority of studies had severe/critical risk of bias; there is impactful heterogeneity across studies—and for ovarian cancer, publication bias; and causal inference requires temporality, which in many studies was not considered. We discuss the implications of these potential associations from the perspectives of patients with endometriosis, clinicians involved in their care, and scientists investigating their long-term health risks.
- Published
- 2021
46. P–327 Patients’ perspectives on how to improve the management of endometriosis in France: The ComPaRe-Endometriosis cohort
- Author
-
Philippe Ravaud, E Diard, I Pane, M Gabillet, C Riveros, C Garoche, Marina Kvaskoff, S Gouesbet, and Viet-Thi Tran
- Subjects
medicine.medical_specialty ,Reproductive Medicine ,Obstetrics ,business.industry ,Rehabilitation ,Cohort ,medicine ,Endometriosis ,Obstetrics and Gynecology ,business ,medicine.disease - Abstract
Study question How should endometriosis management be improved from the patient’s point of view? Summary answer One thousand endometriosis patients proposed 2,587 ideas to improve the management of endometriosis that reflect three main themes: diagnosis, care, and information on the disease. What is known already Endometriosis is a gynecologic condition affecting 10% of reproductive-age women. The disease causes severe pelvic pain and has a dramatic impact on women’s quality of life. A mean delay of 7 years was described between onset of symptoms and diagnosis. There is an urgent need to reduce this delay and to rethink endometriosis care in order to adopt a more comprehensive and patient-centered approach, as women are often dissatisfied with the care they receive. Study design, size, duration This study was carried out in a random sample of endometriosis patients participating in ComPaRe (Community of Patients for Research), a prospective e-cohort of adult chronic disease patients who will be followed-up for 10 years. Participants complete monthly online questionnaires about their life with their disease(s). Recruitment began in January 2017 and is still ongoing, with currently 44,000 participants, including 10,000 endometriosis patients in the ComPaRe-Endometriosis sub-cohort. Participants/materials, setting, methods We selected a random sample of 1,000 participants in ComPaRe-Endometriosis, forming 3 equal groups of age (45 years old) and education (14 years). We conducted a qualitative study to gather their ideas for improving the management of their disease. Participants were asked: “If you had a magic wand, what would you change in your health care?”. One interviewer and two patients independently extracted ideas from the open-ended responses using thematic analysis. Main results and the role of chance Patients proposed a total of 2,587 ideas to improve the management of endometriosis, which we classified in three main themes: diagnosis, care, and information on the disease. To improve diagnosis, women proposed 724 ideas classified into 11 areas of improvement, including training of health professionals, taking symptoms seriously, improving the diagnosis process, and recognition of the disease by clinicians. To improve care, patients gave 1,677 ideas classified into 71 areas of improvement. For example, they asked for a better pain management, more listening from caregivers, the reimbursement of care or medical treatments, help in accessing clinicians that are expert in endometriosis, and reduced waiting times for medical appointments and exams. Finally, to improve information on the disease, participants suggested 186 ideas classified into 5 areas of improvement, covering more explanation about the disease, public recognition of endometriosis and general awareness, and more research and more explanation of research results. Limitations, reasons for caution The results were reviewed by three people in order to reduce the margin of interpretation in the analysis of this open-ended question, but some subjectivity remains. Generalizability may be difficult because the results are linked to the specificities of the French model of care. Wider implications of the findings: Through the many ideas proposed by patients, we identified a total of 87 areas for improvement in endometriosis diagnosis, care, and information. These results reflect patients’ expectations in terms of management of their disease and will be useful to design a better global care for endometriosis from the patients’ perspective. Trial registration number Not applicable
- Published
- 2021
47. When mentoring matters: a French mentoring program for women in science
- Author
-
Julie Batut, Marina Kvaskoff, May C. Morris, Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Unité de biologie moléculaire, cellulaire et du développement (MCD), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre de Biologie Intégrative (CBI), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, KARLI, Mélanie, Unité de biologie moléculaire, cellulaire et du développement - UMR5077 (MCD), Centre de Biologie Intégrative (CBI), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)
- Subjects
0303 health sciences ,Medical education ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,ComputingMilieux_THECOMPUTINGPROFESSION ,4. Education ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,[SDV]Life Sciences [q-bio] ,Biomedical Engineering ,MEDLINE ,Bioengineering ,Applied Microbiology and Biotechnology ,[SDV] Life Sciences [q-bio] ,ComputingMilieux_GENERAL ,03 medical and health sciences ,0302 clinical medicine ,Molecular Medicine ,Women in science ,Sociology ,ComputingMethodologies_GENERAL ,030217 neurology & neurosurgery ,030304 developmental biology ,Biotechnology - Abstract
International audience; An innovative program addresses the need for support, encouragement and guidance on the part of women scientists in the early years of their career, during their PhD.
- Published
- 2021
48. Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study
- Author
-
M Al Rahmoun, Yahya Mahamat-Saleh, Marina Kvaskoff, Agnès Fournier, Marie-Christine Boutron-Ruault, Isabelle Savoye, and Iris Cervenka
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Hazard ratio ,medicine.disease ,Confidence interval ,Menopause ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Internal medicine ,Cutaneous melanoma ,Epidemiology ,Medicine ,Skin cancer ,business ,Prospective cohort study ,Cohort study - Abstract
Cutaneous melanoma has been suspected to be influenced by female hormones. Several studies reported a positive association between menopausal hormone therapy (MHT) use and melanoma risk; however, previous findings were conflicting. We sought to explore the associations between MHT use and melanoma risk in a prospective cohort of women in France, where a particularly wide variety of MHT formulations are available. E3N is a prospective cohort of 98,995 French women aged 40-65 years in 1990. MHT use was assessed through biennial self-administered questionnaires. We used Cox proportional hazards regression models adjusted for age and skin cancer risk factors. Over 1990-2008, 444 melanoma cases were ascertained among 75,523 postmenopausal women. Ever use of MHT was associated with a higher melanoma risk (hazard ratio (HR) = 1.35, 95% confidence intervals (CI) = 1.07-1.71). The association was strongest among past users (HR = 1.55, CI = 1.17-2.07, homogeneity for past vs. recent use: p = 0.11), and users of MHT containing norpregnane derivatives (HR = 1.59, CI = 1.11-2.27), although with no heterogeneity across types of MHT (p = 0.13). Among MHT users, the association was similar across durations of use. However, a higher risk was observed when treatment onset occurred shortly after menopause (
- Published
- 2019
49. Statin Use and Skin Cancer Risk: A Prospective Cohort Study
- Author
-
Trude Eid Robsahm, Agnès Fournier, Yahya Mahamat-Saleh, Reza Ghiasvand, Marina Kvaskoff, Manon Cairat, Marie-Christine Boutron-Ruault, Iris Cervenka, Marie Al Rahmoun, Gianluca Severi, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Oslo University Hospital [Oslo], Cancer Registry of Norway, International Agency for Cancer Research (IACR), Università degli Studi di Firenze = University of Florence (UniFI), 2102 918823, NCT03285230, Centre International de Recherche sur le Cancer, CIRC, Agence Nationale de la Recherche, ANR: ANR-10-COHO-0006, Institut National de la Santé et de la Recherche Médicale, Inserm, Institut National Du Cancer, INCa: INCa_13539, Institut Gustave-Roussy, Mutuelle Générale de l'Education Nationale, MGEN, We are grateful to the study participants for their continued participation and to practitioners for providing pathology reports. We also thank all members of the E3N study group, particularly Rafika Cha?t, Ghizlane Bajawi-Esselma, Amandine Gelot, Marie Fangon, Pascale Gerbouin-R?rolle, Sabine Moreira-Faria, Nad?ge Senina, Sofiane Harizi, Lyan Hoang, Anita Kowal, and Camille Laplanche for their technical assistance. The E3N cohort from the French National Institute of Health and Medical Research (Inserm) was supported by the Mutuelle G?n?rale de l'Education Nationale, the Gustave Roussy Institute, and the French League against Cancer. E3N-E4N is also supported by the French National Research Agency under the Investment for the Future Program (ANR-10-COHO-0006) and by the French Ministry of Higher Education, Research and Innovation (subsidy for public service charges #2102 918823). MAR, YMS, and IC were supported by research scholarships from the French National Cancer Institute (MAR: INCa_13539), the Paris Ile-de-France region, and the French Ministry of Research, respectively. This study is listed at ClinicalTrials.gov as NCT03285230. The work reported in this paper was performed during Agn?s Fournier's term as a Visiting Scientist at the International Agency for Research on Cancer. Conceptualization: MK, AF, Data Curation: MAR, AF, Formal Analysis: MAR, Funding Acquisition: MAR, MK, AF, Investigation: MAR, MK, AF, Methodology: MK, AF, Project Administration: MK, AF, Resources: GS, MCBR, MK, AF, Software: MAR, AF, Supervision: MK, AF, Visualization: MAR, Validation: MK, AF, Writing - Original Draft Preparation: MAR, RG, TER, MK, AF, Writing - Review and Editing: MAR, RG, MC, YMS, IC, GS, MCBR, TER, MK, AF, Funding sources had no role in study design, collection, analysis, and interpretation of data, writing of the report, and the decision to submit the article for publication., ANR-10-COHO-0006,E4N,Etude Epidémiologique des Enfants de femmes de l'Education Nationale(2010), HAL UVSQ, Équipe, and Cohortes - Etude Epidémiologique des Enfants de femmes de l'Education Nationale - - E4N2010 - ANR-10-COHO-0006 - COHO - VALID
- Subjects
Male ,medicine.medical_specialty ,Skin Neoplasms ,[SDV]Life Sciences [q-bio] ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Dermatology ,Biochemistry ,Cohort Studies ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Risk Factors ,Internal medicine ,Epidemiology ,medicine ,Humans ,Basal cell carcinoma ,Prospective Studies ,Prospective cohort study ,Melanoma ,Molecular Biology ,Proportional Hazards Models ,Aged, 80 and over ,business.industry ,Hazard ratio ,Cell Biology ,[SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology ,medicine.disease ,Confidence interval ,[SDV] Life Sciences [q-bio] ,Defined daily dose ,Carcinoma, Basal Cell ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Carcinoma, Squamous Cell ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Female ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Skin cancer ,business ,Body mass index ,[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology - Abstract
International audience; Epidemiological studies on statin use in relation to skin cancer risk are scarce and yielded conflicting results. We explored this association in Etude Epidémiologique auprès de femmes de l'Education Nationale, a prospective cohort of French women born in 1925–1950. Health and lifestyle data were self-reported biennially and matched with drug reimbursement data, allowing the identification of participants’ statin use since 2004. Multivariable cause-specific hazards regression models adjusted for skin cancer risk factors estimated hazard ratios with 95% confidence intervals. Over 2004–2014, 455 cutaneous melanoma, 1,741 basal cell carcinoma, and 268 squamous cell carcinoma cases were ascertained among 62,473 women. Compared with never use, there were no associations between ever use of statins and melanoma (hazard ratio = 1.16, 95% confidence interval = 0.94–1.44) or squamous cell carcinoma (hazard ratio = 0.89, 95% confidence interval = 0.66–1.19) risks and a decrease in basal cell carcinoma risk with ever use of statins (hazard ratio = 0.89, 95% confidence interval = 0.79–0.996). We found no trend of increasing or decreasing risks with dose, duration of use, time since first use, or age at first use and no statistically significant effect modification by pigmentary traits or residential UVR exposure. Because of the limited number of studies evaluating the associations between the use of statins and the risks of melanoma, basal cell carcinoma, and squamous cell carcinoma, these findings would deserve further investigation in other settings.
- Published
- 2022
50. A commentary on the need for support with mental as well as physical health for people with endometriosis during the COVID-19 pandemic and beyond
- Author
-
Marina Kvaskoff, Beatriz Martínez-Burgo, Lysia Demetriou, Christian M. Becker, Kurtis Garbutt, Adriana Luckow Invitti, Elaine Fox, Krina T. Zondervan, Emma Evans, Katy Vincent, Emma Cox, and Claire E. Lunde
- Subjects
medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Pandemic ,Endometriosis ,medicine ,Physical health ,medicine.disease ,Psychiatry ,business - Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.